id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1201253398059896833,1201253398059896833,2019-12-02 03:05:02 IST,2019-12-02,03:05:02,+0530,25998862,drugchannels,Adam J. Fein,,We still have #GrossToNetBubble problem: 1. Humira's list price skyrockets 2. Net price received by @abbvie $ABBV grows slowly b/c of #PBM #rebates 3. Plans use $$ to reduce premiums for healthy 4. Patient OOP grows along with list--not net--price (reverse insurance)  Crazy!,en,"[{'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",[],[],2,19,51,"['grosstonetbubble', 'pbm', 'rebates']",['abbv'],https://twitter.com/DrugChannels/status/1201253398059896833,False,https://twitter.com/EricTopol/status/1200850777524166658,0,,,,,,,,[],,,,
1201004888412450817,1201004888412450817,2019-12-01 10:37:33 IST,2019-12-01,10:37:33,+0530,359256491,lehman1980,„Çä„Éº„Åæ„ÇìüçªÂüºÁéâ„Åå„Å£„Å°„ÇäÂ§ßÂÆ∂üá∫üá∏üç∂,,ABBV„ÅÆÊó•Êú¨Ê≥ï‰∫∫„ÄÄ„Ç¢„ÉÉ„É¥„Ç£ÂêàÂêå‰ºöÁ§æ„ÅÆTVCMÂàù„ÇÅ„Å¶Ë¶ã„ÅüÔºÅ Êó•Êõú„Éü„Çπ„ÉÜ„É™„Éº„ÅÆ„Çπ„Éù„É≥„Çµ„Éº„Åø„Åü„ÅÑ„ÄÇ  #abbvie  #„ÉÜ„É¨„ÉìÊù±‰∫¨   https://t.co/BifPD7ZXgc,ja,[],['https://www.abbvie.co.jp/our-company/company-overview.html'],[],0,1,14,"['abbvie', '„ÉÜ„É¨„ÉìÊù±‰∫¨']",[],https://twitter.com/Lehman1980/status/1201004888412450817,False,,0,,,,,,,,[],,,,
1193870149151084544,1193870149151084544,2019-11-11 18:06:39 IST,2019-11-11,18:06:39,+0530,886220179851665408,alphacharts365,Jack,,$ABBV Abbvie never gave me a second chance to get in...  https://t.co/qw4xScbXgO,en,[],[],['https://pbs.twimg.com/media/EJF6kdIXkAIU1J9.png'],4,0,11,[],['abbv'],https://twitter.com/alphacharts365/status/1193870149151084544,False,,1,https://pbs.twimg.com/media/EJF6kdIXkAIU1J9.png,,,,,,,[],,,,
1193151014871949313,1193151014871949313,2019-11-09 18:29:04 IST,2019-11-09,18:29:04,+0530,401575573,dividendc2,dividendc2,,Mis TOP5 mejores compa√±√≠as largo plazo  LONGEVIDAD - Combatir el Envejecimiento  1: Medtronic PLC $MDT  2: Stryker Corp $SYK  3: Novo Nordisk A / S $NOVO.B: CPH  4: Boston Scientific Corporation $BSX  5: AbbVie Inc $ABBV,es,[],[],[],1,3,7,[],"['mdt', 'syk', 'novo.b', 'bsx', 'abbv']",https://twitter.com/dividendc2/status/1193151014871949313,False,,0,,,,,,,,[],,,,
1192904641660510208,1192904641660510208,2019-11-09 02:10:04 IST,2019-11-09,02:10:04,+0530,2499229069,dvdnddiplomats,Dividend Diplomats,,"Disney, Nike, Hormel, and AbbVie.     There are some HUGE #dividend paying companies that are expected to announce dividend increase in November.   $NKE $KRL $DIS $ABBV $MKC #Investing #DividendGrowthStocks #PersonalFinance",en,[],[],[],0,0,8,"['dividend', 'investing', 'dividendgrowthstocks', 'personalfinance']","['nke', 'krl', 'dis', 'abbv', 'mkc']",https://twitter.com/DvdndDiplomats/status/1192904641660510208,False,,0,,,,,,,,[],,,,
1191704230916239360,1191704230916239360,2019-11-05 18:40:04 IST,2019-11-05,18:40:04,+0530,2499229069,dvdnddiplomats,Dividend Diplomats,,"Disney, Nike, Hormel, and AbbVie.     There are some HUGE #dividend paying companies that are expected to announce dividend increase in November.   How many do you own?    $NKE $KRL $DIS $ABBV $MKC #Investing #DividendGrowthStocks #PersonalFinance   https://t.co/jsXyagGZHX",en,[],['https://www.dividenddiplomats.com/expected-dividend-increases-in-november-2019/'],[],0,0,7,"['dividend', 'investing', 'dividendgrowthstocks', 'personalfinance']","['nke', 'krl', 'dis', 'abbv', 'mkc']",https://twitter.com/DvdndDiplomats/status/1191704230916239360,False,,0,,,,,,,,[],,,,
1190553250724012032,1190553250724012032,2019-11-02 14:26:29 IST,2019-11-02,14:26:29,+0530,925652822716186624,fire_stratege,FIRE-Strategie,,"Mit dem gestrigen Kauf von $MMM und $ABBV eine Voraussetzung f√ºr die #Ziele in 2020 erf√ºllt: jeden Monat #Dividende erhalten. Gut f√ºr das #Depot, gro√üartig f√ºr die #Motivation  #3M #abbvie #dividend #firestrategie",de,[],[],[],4,0,13,"['ziele', 'dividende', 'depot', 'motivation', '3m', 'abbvie', 'dividend', 'firestrategie']","['mmm', 'abbv']",https://twitter.com/FIRE_Stratege/status/1190553250724012032,False,,0,,,,,,,,[],,,,
1190391816991989761,1190391816991989761,2019-11-02 03:45:00 IST,2019-11-02,03:45:00,+0530,3377328194,hiromethods,Ë§áÂà©„ÅÆ„ÉÅ„Ç´„É©„ÅßÂÑÑ„Çä‰∫∫ÔΩúÈÄ£Á∂öÂ¢óÈÖçÊ†™„Åß„Çª„Éü„É™„Çø„Ç§„Ç¢„ÇíÂøúÊè¥„Åô„Çã„Éñ„É≠„Ç∞,,„Ç¢„ÉÉ„É¥„Ç£(ABBV)„Åå10.3ÔºÖ„ÅÆÂ¢óÈÖç„ÇíÁô∫Ë°®„Åß„Åô‚òÄÔ∏è ÈÖçÂΩìÂà©Âõû„Çä„ÅØ„ÄÅ11/1(Èáë)ÁµÇÂÄ§„Éô„Éº„Çπ„Åß5.77ÔºÖ„Å®„Å™„Å£„Å¶„ÅÑ„Åæ„Åô„ÄÇ $ABBV - AbbVie declares $1.18 dividend  https://t.co/hePyZYpkga,ja,[],['https://seekingalpha.com/news/3512986-abbvie-declares-1_18-dividend?source=tweet'],[],0,19,115,[],['abbv'],https://twitter.com/hiromethods/status/1190391816991989761,False,,0,,,,,,,,[],,,,
1190350590162817026,1190350590162817026,2019-11-02 01:01:10 IST,2019-11-02,01:01:10,+0530,1132120019268014081,pantsuhaunko,„Éë„É≥„ÉÑÂêõ,,„Åª„ÇâÔºÅÂ¢óÈÖç„ÅÜ„Çå„Åó„Éº!  $ABBV - AbbVie declares $1.18 dividend  https://t.co/B02qGxzHns  https://t.co/pEMFAkvQJt,ja,[],"['https://seekingalpha.com/news/3512986-abbvie-declares-1_18-dividend?source=tweet', 'https://seekingalpha.com/news/3512986-abbvie-declares-1_18-dividend']",[],2,0,11,[],['abbv'],https://twitter.com/pantsuhaunko/status/1190350590162817026,False,,0,,,,,,,,[],,,,
1190316550663880704,1190316550663880704,2019-11-01 22:45:55 IST,2019-11-01,22:45:55,+0530,225387105,missioncashflow,Ingo Scholtz,,"AbbVie Inc. (ABBV) erh√∂ht die Quartalsdividende um 10,3% von 1,07 auf 1,18 USD. Die Dividendenrendite steigt damit auf 5,9%. Strike! Der n√§chste Zahltag ist der 14.2.20.  https://t.co/NHkJpeXFff #Aktien #B√∂rse #Dividende #Zahltagstrategie #Dividendenstrategie #AbbVie #ABBV",de,[],['https://mission-cashflow.de/juni-2019-kauf-von-abbvie/'],[],2,0,12,"['aktien', 'b√∂rse', 'dividende', 'zahltagstrategie', 'dividendenstrategie', 'abbvie', 'abbv']",[],https://twitter.com/MissionCashflow/status/1190316550663880704,False,,0,,,,,,,,[],,,,
1190259362352250880,1190259362352250880,2019-11-01 18:58:40 IST,2019-11-01,18:58:40,+0530,2723696479,dividendhike,dividend hike,,#AbbVie hikes dividend by 10.3 percent. $ABBV,en,[],[],[],2,15,60,['abbvie'],['abbv'],https://twitter.com/dividendhike/status/1190259362352250880,False,,0,,,,,,,,[],,,,
1190254209939189761,1190254209939189761,2019-11-01 18:38:12 IST,2019-11-01,18:38:12,+0530,790839114685906944,invirtiendopap,InvirtiendoPocoaPoco,,"$ABBV (Abbvie) pagar√° un dividendo de 1,18$ brutos por acci√≥n el 14 de Febrero.   Este pago supone un aumento del 10,28% con respecto al del a√±o anterior (1,07$).  Abbvie tiene un incremento medio de los dividendos del 18,98% en los √∫ltimos 5 a√±os...Casi nada.   #dividendos  https://t.co/DQrLHWeMlH",es,[],[],['https://pbs.twimg.com/media/EISh5KRXUAANo_0.png'],4,2,26,['dividendos'],['abbv'],https://twitter.com/InvirtiendoPaP/status/1190254209939189761,False,,1,https://pbs.twimg.com/media/EISh5KRXUAANo_0.png,,,,,,,[],,,,
1190243931545489408,1190243931545489408,2019-11-01 17:57:21 IST,2019-11-01,17:57:21,+0530,74624978,gonchan0810,gonchan0810,,10.3%„ÅÆÂ¢óÈÖç„Åß„Åô! AbbVie declares $1.18 dividend  https://t.co/DM8PgSzFnJ $ABBV,ja,[],['https://seekingalpha.com/news/3512986?source=ansh'],[],0,2,7,[],['abbv'],https://twitter.com/gonchan0810/status/1190243931545489408,False,,0,,,,,,,,[],,,,
1190240825374105602,1190240825374105602,2019-11-01 17:45:01 IST,2019-11-01,17:45:01,+0530,214234989,richard_jg,Richard_IFI,,"AbbVie declares $1.18 dividend $ABBV me ha subido el sueldo un 10%, as√≠ da gusto... compensa la congelaci√≥n de $REE  https://t.co/EsDhZCRS4T",es,[],['https://seekingalpha.com/news/3512986'],[],2,0,9,[],"['abbv', 'ree']",https://twitter.com/richard_jg/status/1190240825374105602,False,,0,,,,,,,,[],,,,
1190237290980708352,1190237290980708352,2019-11-01 17:30:58 IST,2019-11-01,17:30:58,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q3'19 EPS(Non-GAAP) $2.33 ‰∫àÊÉ≥Ôºã$0.03 Â£≤‰∏ä $8.48B (+3% Y/Y) ‰∫àÊÉ≥Ôºã$100M  2018Âπ¥„Å´‰∏ñÁïå„ÅßÊúÄ„ÇÇÂ£≤„Çå„ÅüËñ¨„Åß„ÅÇ„Çã„Éí„É•„Éü„É©Q3Â£≤‰∏äÈ´ò $4.936B  Ê†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß+1.2%  https://t.co/vOWGAt8HhD  https://t.co/NUoLv0w0sp,ja,[],['https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2019-financial-results'],['https://pbs.twimg.com/media/EISSfPfW4AENdWn.jpg'],0,23,65,[],[],https://twitter.com/KessanMan/status/1190237290980708352,False,,1,https://pbs.twimg.com/media/EISSfPfW4AENdWn.jpg,,,,,,,[],,,,
1187714030259097600,1187714030259097600,2019-10-25 18:24:26 IST,2019-10-25,18:24:26,+0530,102754598,johncendpts,John Carroll,,"AbbVie doubles down on cystic fibrosis R&amp;D, adding a new drug to the pipeline as Vertex seals its domination of the field with Trikafta OK $ABBV $VRTX  https://t.co/dLVKZGgCai",en,[],['https://endpts.com/abbvie-doubles-down-on-cystic-fibrosis-rd-adding-a-new-drug-to-the-pipeline-as-vertex-seals-its-domination-of-the-field-with-trikafta-ok/'],[],1,1,8,[],"['abbv', 'vrtx']",https://twitter.com/JohnCendpts/status/1187714030259097600,False,,0,,,,,,,,[],,,,
1186076732018835462,1186076732018835462,2019-10-21 05:58:23 IST,2019-10-21,05:58:23,+0530,801116888,cfromhertz,Christian Fromhertz,,$ABBV AbbVie Inc.   first close &gt; 200d MA since Jun'18  https://t.co/Ff9nLX1D4f,en,[],[],['https://pbs.twimg.com/media/EHXKfydW4AA4SWd.png'],1,1,12,[],['abbv'],https://twitter.com/cfromhertz/status/1186076732018835462,False,,1,https://pbs.twimg.com/media/EHXKfydW4AA4SWd.png,,,,,,,[],,,,
1185285709088866306,1185285709088866306,2019-10-19 01:35:09 IST,2019-10-19,01:35:09,+0530,886220179851665408,alphacharts365,Jack,,$ABBV Abbvie breaking its downtrend and yielding 5.7%  https://t.co/sDTVVg2Zmy,en,[],[],['https://pbs.twimg.com/media/EHL7EYsXYAQGjt0.png'],0,4,34,[],['abbv'],https://twitter.com/alphacharts365/status/1185285709088866306,False,,1,https://pbs.twimg.com/media/EHL7EYsXYAQGjt0.png,,,,,,,[],,,,
1184511630127910915,1184511630127910915,2019-10-16 22:19:14 IST,2019-10-16,22:19:14,+0530,2379395095,therealpetrusko,petrusko,,Here is Why Growth Investors Should Buy AbbVie (ABBV) Now  https://t.co/oZ81euvkhL via @YahooFinance,en,"[{'screen_name': 'yahoofinance', 'name': 'yahoo finance', 'id': '19546277'}]",['https://finance.yahoo.com/news/why-growth-investors-buy-abbvie-124512538.html?soc_src=hl-viewer&soc_trk=tw'],[],1,3,23,[],[],https://twitter.com/therealpetrusko/status/1184511630127910915,False,,0,,,,,,,,[],,,,
1183883150285516800,1183854424306921477,2019-10-15 04:41:53 IST,2019-10-15,04:41:53,+0530,1444415941,brendan_49,brendan,,The $ABBV story is insane. Paying $450m in 2010. Waiting a decade. And bailing one week before pivotal success - w/ a string of readouts due in next couple years? Brutal. It's gotta be situation where the people at Abbvie who believed in $RETA are long gone.,en,[],[],[],3,0,8,[],"['abbv', 'reta']",https://twitter.com/brendan_49/status/1183883150285516800,False,,0,,,,,,,,[],,,,
1177789028713865216,1177789028713865216,2019-09-28 09:06:01 IST,2019-09-28,09:06:01,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,$ABBV AbbVie ....Interesting look here given the weakness of other Pharma stocks and ETFs like $PJP and $PPH  https://t.co/torRU9UOL8,en,[],[],['https://pbs.twimg.com/media/EFhY3e2X0AAk1Zu.jpg'],4,5,29,[],"['abbv', 'pjp', 'pph']",https://twitter.com/the_chart_life/status/1177789028713865216,False,,1,https://pbs.twimg.com/media/EFhY3e2X0AAk1Zu.jpg,,,,,,,[],,,,
1177315151038623745,1177315151038623745,2019-09-27 01:43:00 IST,2019-09-27,01:43:00,+0530,1138550386875351040,jmcnichol_tda,John McNichol,,Abbvie $ABBV has formed a bowl formation with Relative Strength against $SPX rising. Is Abbvie setting up to break its 18 month downtrend? #chartlife #pricepattern  https://t.co/ic6zzFCioI,en,[],[],['https://pbs.twimg.com/media/EFap4ygWsAEIKXf.jpg'],3,3,11,"['chartlife', 'pricepattern']","['abbv', 'spx']",https://twitter.com/JMcNichol_TDA/status/1177315151038623745,False,,1,https://pbs.twimg.com/media/EFap4ygWsAEIKXf.jpg,,,,,,,[],,,,
1177208700647485440,1177208700647485440,2019-09-26 18:40:00 IST,2019-09-26,18:40:00,+0530,183367527,etfedgecnbc,CNBC's ETF Edge,,The Biotech ETF ticking higher in the premarket after Citi upgraded AbbVie to ‚Äòbuy‚Äô after the company‚Äôs acquisition of Allergan $XBI $ABBV  https://t.co/um642yjZpg,en,[],[],['https://pbs.twimg.com/media/EFZJEpwX4AAiIYj.jpg'],1,2,3,[],"['xbi', 'abbv']",https://twitter.com/ETFEdgeCNBC/status/1177208700647485440,False,,1,https://pbs.twimg.com/media/EFZJEpwX4AAiIYj.jpg,,,,,,,[],,,,
1176949692560752641,1176949692560752641,2019-09-26 01:30:48 IST,2019-09-26,01:30:48,+0530,214234989,richard_jg,Richard_IFI,,"Hoy he incorporado 3 nuevas empresas a mi cartera: - Allianz  $ALV a 208,45‚Ç¨ (pinaneo) - Abbvie $ABBV a 72,86$ (mini compra) - Peocter&amp;Gamble $PG a 123,40$ (mini compra) Con Yields del 4.3%, 5.9% y 2,4% respectivamente.",es,[],[],[],5,1,26,[],"['alv', 'abbv', 'pg']",https://twitter.com/richard_jg/status/1176949692560752641,False,,0,,,,,,,,[],,,,
1171322834116911105,1171322834116911105,2019-09-10 12:51:40 IST,2019-09-10,12:51:40,+0530,790839114685906944,invirtiendopap,InvirtiendoPocoaPoco,,"$ABBV (Abbvie) pagar√° un dividendo de 1,07$ brutos por acci√≥n el 15 de Noviembre.   A√±adido a nuestro #divippcalendario como de costumbre.   #dividendos #buyandhold",es,[],[],[],2,3,22,"['divippcalendario', 'dividendos', 'buyandhold']",['abbv'],https://twitter.com/InvirtiendoPaP/status/1171322834116911105,False,,0,,,,,,,,[],,,,
1168893910845927424,1168893910845927424,2019-09-03 20:00:00 IST,2019-09-03,20:00:00,+0530,790839114685906944,invirtiendopap,InvirtiendoPocoaPoco,,Otra que nos salta.  Compramos $ABBV (Abbvie) a 65$  Van a entrar todas (falta una) porque las pusimos un poquit√≠n por debajo de lo que cerraron el Viernes.   Este mes va a ser tranquilo üòÖ  #dividendos #buyandhold #compras,es,[],[],[],2,0,12,"['dividendos', 'buyandhold', 'compras']",['abbv'],https://twitter.com/InvirtiendoPaP/status/1168893910845927424,False,,0,,,,,,,,[],,,,
1167120912191295488,1167120912191295488,2019-08-29 22:34:44 IST,2019-08-29,22:34:44,+0530,211220879,frankvinluan,Frank Vinluan,,"3 years ago, AbbVie paid $5.8B for Stemcentrx to get ahold of its lead #cancer drug hoping it would help the company diversify beyond Humira. Today, $ABBV threw in the towel on the drug after it failed to beat a placebo in a Phase 3 trial  https://t.co/O6b7xy6CBj",en,[],['https://xconomy.com/detroit-ann-arbor/2019/08/29/5-8b-for-nothing-abbvie-shelves-stemcentryx-drug-after-latest-flop/'],[],0,2,7,['cancer'],['abbv'],https://twitter.com/frankvinluan/status/1167120912191295488,False,,0,,,,,,,,[],,,,
1162437452071604225,1162437452071604225,2019-08-17 00:24:20 IST,2019-08-17,00:24:20,+0530,102754598,johncendpts,John Carroll,,"AbbVie gets its FDA OK for JAK inhibitor upadacitinib, but don‚Äôt look for this one to hit execs‚Äô lofty expectations $ABBV  https://t.co/4CjVhsqDA8",en,[],['https://endpts.com/abbvie-gets-its-fda-ok-for-jak-inhibitor-upadacitinib-but-dont-look-for-this-one-to-hit-execs-lofty-expectations/'],[],0,3,11,[],['abbv'],https://twitter.com/JohnCendpts/status/1162437452071604225,False,,0,,,,,,,,[],,,,
1162065675940220929,1162065675940220929,2019-08-15 23:47:01 IST,2019-08-15,23:47:01,+0530,1287074226,perryns69,perryns,,AbbVie: Testing Our Capacity To Suffer  https://t.co/4pvKnbDDKh $ABBV,en,[],['https://seekingalpha.com/article/4283110?source=ansh'],[],0,2,7,[],['abbv'],https://twitter.com/perryns69/status/1162065675940220929,False,,0,,,,,,,,[],,,,
1154939552617893888,1154939552617893888,2019-07-27 07:50:21 IST,2019-07-27,07:50:21,+0530,380711634,presenilin1,Se Hoon Choi,,AbbVie has called a halt to the Phase 2 trial of its anti-tau antibody ABBV-8E12 for progressive supranuclear palsy after it failed a futility analysis. #Alzheimer's    https://t.co/h5Fws9bF5j,en,[],['https://www.alzforum.org/news/research-news/abbvies-tau-antibody-flops-progressive-supranuclear-palsy'],[],1,5,9,['alzheimer'],[],https://twitter.com/presenilin1/status/1154939552617893888,False,,0,,,,,,,,[],,,,
1154771414810943488,1154771414810943488,2019-07-26 20:42:14 IST,2019-07-26,20:42:14,+0530,2333224141,brunovellas,Bruno Vellas,,AbbVie shut down a Phase II trial for the anti-tau drug ABBV-8E12 after investigators determined that the data indicated it was useless to push ahead on a neurodegenerative study for progressive supranuclear palsy. The drug is studied in Alzheimer‚Äôs #Alzheimer,en,[],[],[],2,19,10,['alzheimer'],[],https://twitter.com/brunovellas/status/1154771414810943488,False,,0,,,,,,,,[],,,,
1154739423793373184,1154739423793373184,2019-07-26 18:35:07 IST,2019-07-26,18:35:07,+0530,531892451,abbvie,AbbVie,,We‚Äôre raising 2019 guidance based on continued strong performance of our business. Learn more:  https://t.co/qDmM0PyrQl $ABBV  https://t.co/AMR6EidakB,en,[],['http://bit.ly/30VjJVn'],['https://pbs.twimg.com/media/EAZ1YttWsAIPSrL.jpg'],0,4,10,[],['abbv'],https://twitter.com/abbvie/status/1154739423793373184,False,,1,https://pbs.twimg.com/media/EAZ1YttWsAIPSrL.jpg,,,,,,,[],,,,
1154731600896073728,1154731600896073728,2019-07-26 18:04:02 IST,2019-07-26,18:04:02,+0530,999663757235077122,hibiyatakumi,Êó•ÊØîË∞∑„Çø„ÇØ„Éü üåπË≥áÁî£ÂΩ¢Êàê√ó„Ç≠„É£„É™„Ç¢ÂΩ¢Êàêüåπ,,"ABBV „Ç¢„ÉÉ„É¥„Ç£Â•ΩË™ø„Å™Ê±∫ÁÆó„Å´„Çà„Çä„Éó„É¨„Éû„Éº„Ç±„ÉÉ„Éà„Åß‰∏äÊòá  AbbVie (NYSE: ABBV)   Q2 EPS actual $2.26, forcast $2.20.  Revenue $8.26B forecast $8.10B",ja,[],[],[],0,1,22,[],[],https://twitter.com/Hibiyatakumi/status/1154731600896073728,False,,0,,,,,,,,[],,,,
1154724132052844544,1154724132052844544,2019-07-26 17:34:21 IST,2019-07-26,17:34:21,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q2'19 EPS(Non-GAAP) $2.26 ‰∫àÊÉ≥ +$0.05 Â£≤‰∏ä $8.26B (-0.3% Y/Y) ‰∫àÊÉ≥ +$170M  Êò®Âπ¥ÊúÄ„ÇÇ‰∏ñÁïå„ÅßÂ£≤„Çå„ÅüËñ¨„Éí„É•„Éü„É©„ÅÆ‰ºöÁ§æ„ÄÇ  „Éú„Éà„ÉÉ„ÇØ„Çπ„ÅÆ„Ç¢„É©„Ç¨„É≥Ë≤∑Âèé„ÇíÂÖàÊó•Áô∫Ë°®„Åó„Å¶„ÅÑ„Çã„ÄÇ  Ê†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß+1.9%  https://t.co/hr0UBMswjP  https://t.co/Heb9NWVQpP,ja,[],['https://investors.abbvie.com/static-files/95517fe5-a7db-41ac-825d-3447e4d92a6e'],['https://pbs.twimg.com/media/EAZnZg-UYAMauto.jpg'],1,26,81,[],[],https://twitter.com/KessanMan/status/1154724132052844544,False,,1,https://pbs.twimg.com/media/EAZnZg-UYAMauto.jpg,,,,,,,[],,,,
1153046722165334016,1153046722165334016,2019-07-22 02:28:55 IST,2019-07-22,02:28:55,+0530,1062378513502793728,momiage0088,„ÇÇ„Åø„ÅÇ„Åíüá∫üá∏ Á±≥ÂõΩÊ†™ÊäïË≥á,,AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout @themotleyfool #stocks $ABBV $AGN  https://t.co/Ro9wq0dJmA „Ç¢„ÉÉ„Éì„Ç£Ë≤∑Âèé„Å´„Å§„ÅÑ„Å¶„ÄÅ„Ç¢„ÉÉ„Éì„Ç£„ÅÆÂ§ßÂûã„Éá„Ç£„Éº„É´ÁµåÈ®ì„ÅÆÂº±„Åï„ÇíÊá∏Âøµ„ÄÇ,ja,"[{'screen_name': 'themotleyfool', 'name': 'the motley fool', 'id': '15568127'}]",['https://www.fool.com/investing/2019/07/21/abbvies-acquisitions-report-card-shows-investors-h.aspx'],[],0,2,13,['stocks'],"['abbv', 'agn']",https://twitter.com/momiage0088/status/1153046722165334016,False,,0,,,,,,,,[],,,,
1151235589192028160,1151235589192028160,2019-07-17 02:32:08 IST,2019-07-17,02:32:08,+0530,22446818,ianlopuch,Ian Lopuch,,"Speaking of healthcare and pharma, I‚Äôm proud to see another acquisition from AbbVie ($ABBV). üòé I‚Äôm glad they are positioning themselves for less dependence on Humira. üìà (Disclosure: I am long ABBV) #dividend #investing  https://t.co/nZngTt7SL2",en,[],['https://finance.yahoo.com/news/abbvie-abbv-acquires-mavupharma-boost-150403426.html?.tsrc=applewf'],[],4,0,16,"['dividend', 'investing']",[],https://twitter.com/ianlopuch/status/1151235589192028160,False,,0,,,,,,,,[],,,,
1151177245555167232,1151177245555167232,2019-07-16 22:40:17 IST,2019-07-16,22:40:17,+0530,136640429,nomi_investor,„Éé„Éü„ÅÆÊäïË≥áÂÆ∂@Á±≥ÂõΩÊ†™√óÁ≠ã„Éà„É¨,,ABBV„ÅÆ„Éã„É•„Éº„Çπ„Åß„Åô„ÄÇ‰ªäÂ∫¶„ÅØ„Ç¨„É≥Ê≤ªÁôÇËñ¨Á≥ª„ÅÆ‰ºöÁ§æ„ÇíË≤∑Âèé„Åô„Çã„Çà„ÅÜ„Åß„Åô„ÄÇMÔºÜAÊ¥ªÁô∫„Åß„Åô„Å≠  AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio  https://t.co/yLXgEFIX1E @YahooFinance„Çà„Çä,ja,"[{'screen_name': 'yahoofinance', 'name': 'yahoo finance', 'id': '19546277'}]",['https://finance.yahoo.com/news/abbvie-abbv-acquires-mavupharma-boost-150403426.html?soc_src=community&soc_trk=tw'],[],1,9,63,[],[],https://twitter.com/nomi_investor/status/1151177245555167232,False,,0,,,,,,,,[],,,,
1150740627463835648,1150740627463835648,2019-07-15 17:45:19 IST,2019-07-15,17:45:19,+0530,531892451,abbvie,AbbVie,,NEWS: We just announced we're acquiring Mavupharma to strengthen our #immunooncology early pipeline. Learn more:  https://t.co/cUXZZzK1ln $ABBV #oncology #IO  https://t.co/mMJKHvHu5m,en,[],['http://bit.ly/2YRMl1a'],['https://pbs.twimg.com/media/D_hAgClW4AIv8hJ.jpg'],0,4,16,"['immunooncology', 'oncology', 'io']",['abbv'],https://twitter.com/abbvie/status/1150740627463835648,False,,1,https://pbs.twimg.com/media/D_hAgClW4AIv8hJ.jpg,,,,,,,[],,,,
1149331163196116993,1149331163196116993,2019-07-11 20:24:37 IST,2019-07-11,20:24:37,+0530,790839114685906944,invirtiendopap,InvirtiendoPocoaPoco,,Iniciamos posici√≥n en $ABBV (Abbvie) a 70$.  ¬°Seguimos sumando!  #dividendos #buyandhold #compras,es,[],[],[],1,0,20,"['dividendos', 'buyandhold', 'compras']",['abbv'],https://twitter.com/InvirtiendoPaP/status/1149331163196116993,False,,0,,,,,,,,[],,,,
1147011595010289664,1147011595010289664,2019-07-05 10:47:29 IST,2019-07-05,10:47:29,+0530,401575573,dividendc2,dividendc2,,Mis TOP5 mejores compa√±√≠as - Healthcare -  Longevidad - largo plazo :  1: AbbVie Inc $ABBV  2: Amgen Inc $AMGN   3: Bristol-Myers Squibb Co $BMY  4: Medtronic PLC $MDT  5:  Biogen Inc $BIIB,ca,[],[],[],1,3,13,[],"['abbv', 'amgn', 'bmy', 'mdt', 'biib']",https://twitter.com/dividendc2/status/1147011595010289664,False,,0,,,,,,,,[],,,,
1146376942217830401,1146376269778604033,2019-07-03 16:45:36 IST,2019-07-03,16:45:36,+0530,190773758,sports_bios,Sports_Bios,,"A different kind of scenarios to play out even with the high yields..  when $ABBV was at 6.5% yield, the downside is fairly limited even in a recessionary correction..  obviously, all these companies can cut payout.. but a Macy's Kohl's are more likely to do that vs Abbvie, IMO.",en,[],[],[],0,1,6,[],['abbv'],https://twitter.com/Sports_bios/status/1146376942217830401,False,,0,,,,,,,,[],,,,
1146064058832961537,1146064058832961537,2019-07-02 20:02:19 IST,2019-07-02,20:02:19,+0530,2421030156,suredividend,Sure Dividend,,AbbVie ABBV Stock - Q1 2019 Dividend Safety Update  https://t.co/NEFMUa8VIL  https://t.co/xdJpWgNOjJ,en,[],['https://buff.ly/2KSlBdA'],['https://pbs.twimg.com/media/D-ejL5ZUcAI2qGc.jpg'],1,0,7,[],[],https://twitter.com/SureDividend/status/1146064058832961537,False,,1,https://pbs.twimg.com/media/D-ejL5ZUcAI2qGc.jpg,,,,,,,[],,,,
1144304614847766528,1144304614847766528,2019-06-27 23:30:54 IST,2019-06-27,23:30:54,+0530,234905402,halftimereport,CNBC Halftime Report,,"‚ÄúAbbvie ‚Äì it went down too much on the Allergan deal, I added to my position yesterday morning,‚Äù @GilmanHill‚Äôs Jenny Harrington said.   Also on the traders‚Äô watchlist: Caterpillar, Roku, HealthEquity &amp; Progressive üëá $PGR $ROKU $HQY $CAT $ABBV  https://t.co/UXMYM2Gea5",en,"[{'screen_name': 'gilmanhill', 'name': 'jenny vl harrington', 'id': '2166637968'}]",[],[],0,10,16,[],"['pgr', 'roku', 'hqy', 'cat', 'abbv']",https://twitter.com/HalftimeReport/status/1144304614847766528,False,,1,https://pbs.twimg.com/media/D-Fi-tbXYAURceJ.jpg,,,,,,,[],,,,
1144250238166634497,1144250238166634497,2019-06-27 19:54:50 IST,2019-06-27,19:54:50,+0530,22446818,ianlopuch,Ian Lopuch,,I just initiated my position in AbbVie ($ABBV) at $69.02. $1.07*4=$4.28 #dividends/year. $4.28/$69.02=6.2% starting #dividend yield. Bought a half position. Hope it stays low so I can average into a full position over the coming year. üìâ (Disclosure: I am long ABBV),en,[],[],[],11,1,45,"['dividends', 'dividend']",[],https://twitter.com/ianlopuch/status/1144250238166634497,False,,0,,,,,,,,[],,,,
1144048831484444672,1144048831484444672,2019-06-27 06:34:31 IST,2019-06-27,06:34:31,+0530,1476783300,dgiandr,DGI&R,,Bought more AbbVie Inc. $ABBV today at $67.20.,en,[],[],[],1,1,6,[],['abbv'],https://twitter.com/DGIandR/status/1144048831484444672,False,,0,,,,,,,,[],,,,
1143979594397179904,1143979594397179904,2019-06-27 01:59:24 IST,2019-06-27,01:59:24,+0530,1548736957,mfindustryfocus,Industry Focus,,"What does the megadeal between Allergan and AbbVie have in common with @TMFJMo?  They're both making appearance on this week's Industry Focus Healthcare podcast, with host Shannon Jones.  Don't miss out. Tune in wherever you get podcasts! $AGN $ABBV  https://t.co/ChpYEQbSQj",en,"[{'screen_name': 'tmfjmo', 'name': 'jason a. moser', 'id': '214479702'}]",[],[],0,4,9,[],"['agn', 'abbv']",https://twitter.com/MFIndustryFocus/status/1143979594397179904,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1143979544250109953/pu/img/REasOzbjq8bDjPzA.jpg,,,,,,,[],,,,
1143910135305256963,1143910135305256963,2019-06-26 21:23:23 IST,2019-06-26,21:23:23,+0530,2985017187,7innovator,Simon Erickson,,"1/6 I‚Äôm going to disagree with myself from yesterday and publicly change my mind.  After digging in deeper, I now see why AbbVie $ABBV is eager to acquire Allergan $AGN. And I think this deal makes sense for shareholders.    https://t.co/SFdj1dsVdl",en,[],['https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/allergan/abbvie-allergan-announcement.pdf'],[],7,2,8,[],"['abbv', 'agn']",https://twitter.com/7Innovator/status/1143910135305256963,False,,0,,,,,,,,[],,,,
1143876212282089472,1143876212282089472,2019-06-26 19:08:35 IST,2019-06-26,19:08:35,+0530,20700725,marketsupchuck,Chuck Carnevale,,"$ABBV AbbVie Has It All: Growth, Dividend Growth and Compelling Valuation  https://t.co/c24hwPrM7m via @YouTube",en,"[{'screen_name': 'youtube', 'name': 'youtube', 'id': '10228272'}]",['https://youtu.be/s7EFJOO0f-4'],[],1,4,8,[],['abbv'],https://twitter.com/MarketsUpChuck/status/1143876212282089472,False,,0,,,,,,,,[],,,,
1143875055073595393,1143875055073595393,2019-06-26 19:03:59 IST,2019-06-26,19:03:59,+0530,597078771,emmarcourt,Emma Court,,Hello please enjoy my curated collection of the corniest Wall Street takes on yesterday's $63 billion AbbVie-Allergan deal  The Ariana Grande reference is a personal fave  $abbv $agn  https://t.co/hhIQUZo6xG,en,[],[],"['https://pbs.twimg.com/media/D9_XxZIWwAA0tzD.png', 'https://pbs.twimg.com/media/D9_a22yWsAYYSKJ.png', 'https://pbs.twimg.com/media/D9_bQ2-WsAM5WoO.png', 'https://pbs.twimg.com/media/D9_byMHXsAAn3Fb.png']",1,8,31,[],"['abbv', 'agn']",https://twitter.com/emmarcourt/status/1143875055073595393,False,,1,https://pbs.twimg.com/media/D9_XxZIWwAA0tzD.png,,,,,,,[],,,,
1143802185064570880,421575877994897408,2019-06-26 14:14:26 IST,2019-06-26,14:14:26,+0530,732429464,conkers3,Peter Higgins (conkers),,"@Ishback @wheeliedealer @marben100 @USabadini @talygarntom @dhovekamp42 @MedTechpreneur @A1Mhigh @DianaEPatterson @mattbird55 @Financial_Orbit @AstraZeneca @SandyMidd @contrariansmind @annabelbrodies @sunsuneti1 @categoryx @FiercePharma @AstraZenecaUS @TheRealGMonkee @FoolishFinances @woodfordfunds @Telegraph @DigitalLookNews @CarlyHFierce @ByMadeleineA @BionestPartners @biogerontology @bradloncar @MY21_Oracle @AIMInvestor1978 @Aendryr @Accendo_Mike @TheIdleInvestor @RegHoare @fwpharma @PharmaReview @CNBC @wef @MikeQuindazzi @Sharecastcom @PharmaScrip @Vantageanalysis #AZN ü§îCould we see more #PHARMA/#BIOTECH mna?  @CNNBusiness #AbbVie $ABBV has announced it will buy Ireland-based #Allergan $AGN for $63B, combining the companies behind #Humira &amp; #Botox creating yet another pharmaceutical behemoth  https://t.co/UiYuyCO7sc  https://t.co/epcRsfqh3O",en,"[{'screen_name': 'cnnbusiness', 'name': 'cnn business', 'id': '16184358'}]",['https://cnn.it/2NafUd1'],[],1,7,6,"['azn', 'pharma', 'biotech', 'abbvie', 'allergan', 'humira', 'botox']","['abbv', 'agn']",https://twitter.com/conkers3/status/1143802185064570880,False,,1,https://pbs.twimg.com/media/D97mkYuXUAILdKY.jpg,,,,,,,"[{'screen_name': 'Ishback', 'name': 'Ray&quot;Ishback&quo', 'id': '20905295'}, {'screen_name': 'wheeliedealer', 'name': 'WheelieDealer', 'id': '2822379212'}, {'screen_name': 'marben100', 'name': 'Mark', 'id': '542726415'}, {'screen_name': 'USabadini', 'name': 'Ugo Sabadini', 'id': '466953357'}, {'screen_name': 'talygarntom', 'name': 'Tom', 'id': '773867097726287872'}, {'screen_name': 'dhovekamp42', 'name': ""`((,(Dieter 'Hovekamp)))"", 'id': '67066114'}, {'screen_name': 'MedTechpreneur', 'name': 'Dr. Anna Morera Leralta', 'id': '27005410'}, {'screen_name': 'A1Mhigh', 'name': 'A1Mhigh', 'id': '2817618828'}, {'screen_name': 'DianaEPatterson', 'name': 'Diana', 'id': '3302870909'}, {'screen_name': 'mattbird55', 'name': 'Matthew Bird', 'id': '75736499'}, {'screen_name': 'Financial_Orbit', 'name': 'Chris Bailey', 'id': '1461649975'}, {'screen_name': 'AstraZeneca', 'name': 'AstraZeneca', 'id': '62465691'}, {'screen_name': 'SandyMidd', 'name': 'Sandy', 'id': '361829058'}, {'screen_name': 'contrariansmind', 'name': 'Jeff Robinson, CEO and Chairman of M2bio üåøüçÑ', 'id': '23121787'}, {'screen_name': 'annabelbrodies', 'name': 'Annabel Brodie-Smith', 'id': '2999948183'}, {'screen_name': 'sunsuneti1', 'name': 'Nemo & the sharks', 'id': '229015145'}, {'screen_name': 'categoryx', 'name': 'Simon Rowe', 'id': '29550566'}, {'screen_name': 'FiercePharma', 'name': 'FiercePharma', 'id': '18294275'}, {'screen_name': 'AstraZenecaUS', 'name': 'AstraZenecaUS', 'id': '18723114'}, {'screen_name': 'TheRealGMonkee', 'name': 'G-Monkee', 'id': '142725915'}, {'screen_name': 'FoolishFinances', 'name': 'Foolish Financial', 'id': '729807385783640064'}, {'screen_name': 'woodfordfunds', 'name': 'Woodford', 'id': '2384944496'}, {'screen_name': 'Telegraph', 'name': 'The Telegraph', 'id': '16343974'}, {'screen_name': 'DigitalLookNews', 'name': 'sharecast', 'id': '1548039847'}, {'screen_name': 'CarlyHFierce', 'name': 'Carly Helfand', 'id': '1379301222'}, {'screen_name': 'ByMadeleineA', 'name': 'Madeleine Armstrong', 'id': '14673628'}, {'screen_name': 'BionestPartners', 'name': 'Bionest Partners', 'id': '194586164'}, {'screen_name': 'biogerontology', 'name': 'Alex Zhavoronkov', 'id': '113613491'}, {'screen_name': 'bradloncar', 'name': 'Brad Loncar', 'id': '274233761'}, {'screen_name': 'MY21_Oracle', 'name': 'Mehrdad Yousefi', 'id': '4054643129'}, {'screen_name': 'AIMInvestor1978', 'name': 'AIMInvestor1978', 'id': '3154045473'}, {'screen_name': 'Aendryr', 'name': 'Nandish', 'id': '41104311'}, {'screen_name': 'Accendo_mike', 'name': 'Mike', 'id': '1168826718339158016'}, {'screen_name': 'TheIdleInvestor', 'name': 'Edmund Shing', 'id': '2304454442'}, {'screen_name': 'RegHoare', 'name': 'Reg Hoare', 'id': '402636438'}, {'screen_name': 'fwpharma', 'name': 'FirstWord Pharma', 'id': '35789155'}, {'screen_name': 'PharmaReview', 'name': 'European Pharmaceutical Review', 'id': '132897310'}, {'screen_name': 'CNBC', 'name': 'CNBC', 'id': '20402945'}, {'screen_name': 'wef', 'name': 'World Economic Forum', 'id': '5120691'}, {'screen_name': 'MikeQuindazzi', 'name': 'Mike Quindazzi ‚ú®', 'id': '2344530218'}, {'screen_name': 'Sharecastcom', 'name': 'Sharecast.com', 'id': '45552145'}, {'screen_name': 'PharmaScrip', 'name': 'Scrip', 'id': '21079030'}, {'screen_name': 'vantageanalysis', 'name': 'Evaluate Vantage', 'id': '3033767986'}]",,,,
1143584234445201408,1142473361244790784,2019-06-25 23:48:22 IST,2019-06-25,23:48:22,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,$ABBV AbbVie ...And we have our answer.  https://t.co/NuVP1dRYOl,en,[],[],['https://pbs.twimg.com/media/D97TvDFWsAI5CMH.jpg'],4,1,23,[],['abbv'],https://twitter.com/the_chart_life/status/1143584234445201408,False,,1,https://pbs.twimg.com/media/D97TvDFWsAI5CMH.jpg,,,,,,,[],,,,
1143571169112555524,1143571169112555524,2019-06-25 22:56:27 IST,2019-06-25,22:56:27,+0530,2985017187,7innovator,Simon Erickson,,"At first glance, I am NOT a fan of AbbVie's $ABBV acquisition of Allergan $AGN. I've been an ABBV shareholder for years, but this really seems to have come out of left field.  Still need to dig in deeper, to figure out what exactly they're thinking here.   What are your thoughts?",en,[],[],[],5,1,7,[],"['abbv', 'agn']",https://twitter.com/7Innovator/status/1143571169112555524,False,https://twitter.com/7Innovator/status/1000043169256497154,0,,,,,,,,[],,,,
1143547039772532736,1143547039772532736,2019-06-25 21:20:35 IST,2019-06-25,21:20:35,+0530,102094857,adamfeuerstein,Adam Feuerstein,,The AbbVie and Allergan deal: ‚ÄòTwo turkeys don‚Äôt make an eagle‚Äô  https://t.co/9hXVOUHgIr via @pharmalot w/ props to @matthew_Orr for the turkey photo $ABBV $AGN,en,"[{'screen_name': 'pharmalot', 'name': 'pharmalot', 'id': '13171622'}, {'screen_name': 'matthew_orr', 'name': 'matthew orr', 'id': '24387882'}]",['https://www.statnews.com/pharmalot/2019/06/25/abbvie-allergan-turkeys-humira-merger/'],[],5,10,34,[],"['abbv', 'agn']",https://twitter.com/adamfeuerstein/status/1143547039772532736,False,,0,,,,,,,,[],,,,
1143546418034094080,1143546418034094080,2019-06-25 21:18:06 IST,2019-06-25,21:18:06,+0530,13171622,pharmalot,pharmalot,,The AbbVie and Allergan deal: 'Two turkey's don't make an eagle'... so what do they make? read here..  https://t.co/yT3IUJyANf #pharma $ABBV $AGN #Botox $CELG $BMY $JNJ $RHHBY $ONCE,en,[],['https://www.statnews.com/pharmalot/2019/06/25/abbvie-allergan-turkeys-humira-merger/'],[],1,2,7,"['pharma', 'botox']","['abbv', 'agn', 'celg', 'bmy', 'jnj', 'rhhby', 'once']",https://twitter.com/pharmalot/status/1143546418034094080,False,,0,,,,,,,,[],,,,
1143544864694579201,1143544864694579201,2019-06-25 21:11:56 IST,2019-06-25,21:11:56,+0530,14544185,meghas,Megha Satyanarayana,,"Nice story by @lisamjarvis on the Abbvie/Allergan deal, and how biosimilars play a role. @cenmag $ABBV $AGN  https://t.co/1PffcNNXZq",en,"[{'screen_name': 'lisamjarvis', 'name': 'lisa jarvis', 'id': '84347917'}, {'screen_name': 'cenmag', 'name': 'c&en', 'id': '106542267'}]",['https://cen.acs.org/business/mergers-&-acquisitions/AbbVie-acquire-Allergan-63-billion/97/web/2019/06'],[],0,0,5,[],"['abbv', 'agn']",https://twitter.com/meghas/status/1143544864694579201,False,,0,,,,,,,,[],,,,
1143539067528704012,1143539067528704012,2019-06-25 20:48:54 IST,2019-06-25,20:48:54,+0530,349249475,gerberkawasaki,Ross Gerber,,Stocks mostly red today. Big pharma deal for Botox maker Allergan. Abbvie making a move to be a completely different company now. Good move for them. $abbv $agn,en,[],[],[],4,0,15,[],"['abbv', 'agn']",https://twitter.com/GerberKawasaki/status/1143539067528704012,False,,0,,,,,,,,[],,,,
1143526109004423169,1143526109004423169,2019-06-25 19:57:24 IST,2019-06-25,19:57:24,+0530,19717430,zbiotech,zach,,"*ABBVIE FIRST APPROACHED AGN CEO IN MARCH, AGAIN IN APRIL: CNBC  doesn't take too long to destroy value  $ABBV $AGN",en,[],[],[],2,0,11,[],"['abbv', 'agn']",https://twitter.com/zbiotech/status/1143526109004423169,False,,0,,,,,,,,[],,,,
1143524230912364544,1143524230912364544,2019-06-25 19:49:56 IST,2019-06-25,19:49:56,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,$ABBV Relevant...mega-merger required to hit revenue targets  @abbvie What did it cost you?,en,"[{'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",[],[],0,0,8,[],['abbv'],https://twitter.com/Sanctuary_Bio/status/1143524230912364544,False,https://twitter.com/Sanctuary_Bio/status/1089920860385726464,0,,,,,,,,[],,,,
1143518019433447424,1143518019433447424,2019-06-25 19:25:16 IST,2019-06-25,19:25:16,+0530,106498703,squawkstreet,Squawk on the Street,,BREAKING: Abbvie buys Allergan for $63B in cash and stock  $ABBV $AGN @CNBC @davidfaber  https://t.co/s4GGrCSwu0,en,"[{'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}, {'screen_name': 'davidfaber', 'name': 'david faber', 'id': '140912249'}]",[],[],8,12,27,[],"['abbv', 'agn']",https://twitter.com/SquawkStreet/status/1143518019433447424,False,,1,https://pbs.twimg.com/media/D96Xk0LWwAAGstu.jpg,,,,,,,[],,,,
1143507704364900353,1143507704364900353,2019-06-25 18:44:16 IST,2019-06-25,18:44:16,+0530,2499229069,dvdnddiplomats,Dividend Diplomats,,Woah! Major news for us $ABBV shareholders  AbbVie to buy Botox-maker Allergan in a $63 billion cash-and-stock deal -  https://t.co/c8yibuaBg4,en,[],['https://www.cnbc.com/2019/06/25/abbvie-is-nearing-a-deal-to-buy-allergan-for-more-than-60-billion-wsj.html'],[],8,1,7,[],['abbv'],https://twitter.com/DvdndDiplomats/status/1143507704364900353,False,,0,,,,,,,,[],,,,
1143477732103340033,1143477732103340033,2019-06-25 16:45:10 IST,2019-06-25,16:45:10,+0530,404422077,squawkcnbc,Squawk Box,,"BREAKING: AbbVie is buying Allergan for $188.24/share in a $63B deal. $ABBV $AGN More from the reporter who broke the story, @jonathanrockoff:  https://t.co/lzjDtx1KLs",en,"[{'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}]",[],[],3,11,37,[],"['abbv', 'agn']",https://twitter.com/SquawkCNBC/status/1143477732103340033,False,,1,https://pbs.twimg.com/media/D95y7yZXoAAf1qf.jpg,,,,,,,[],,,,
1143477487797776384,1143477487797776384,2019-06-25 16:44:12 IST,2019-06-25,16:44:12,+0530,801116888,cfromhertz,Christian Fromhertz,,$ABBV $AGN AbbVie in $63 Billion Deal to Buy Botox Maker Allergan  https://t.co/BBLwIGojzh,en,[],[],['https://pbs.twimg.com/media/D95ytolXoAEylab.jpg'],2,3,11,[],"['abbv', 'agn']",https://twitter.com/cfromhertz/status/1143477487797776384,False,,1,https://pbs.twimg.com/media/D95ytolXoAEylab.jpg,,,,,,,[],,,,
1143473206805827584,1143473206805827584,2019-06-25 16:27:11 IST,2019-06-25,16:27:11,+0530,531892451,abbvie,AbbVie,,#BreakingNews: $ABBV announces transformative transaction to acquire @Allergan. Read the release:  https://t.co/Tn07mMbv2Z  https://t.co/dR1kkfwpaP,en,[],['http://bit.ly/2IIT5cj'],['https://pbs.twimg.com/media/D95u0kKXYAA6G0m.jpg'],1,12,36,['breakingnews'],['abbv'],https://twitter.com/abbvie/status/1143473206805827584,False,,1,https://pbs.twimg.com/media/D95u0kKXYAA6G0m.jpg,,,,,,,[],,,,
1143470372857290752,1143470372857290752,2019-06-25 16:15:56 IST,2019-06-25,16:15:56,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,Official PR.  $ABBV AbbVie  to Acquire $AGN in Transformative Move for Both Companies,en,[],[],[],1,5,8,[],"['abbv', 'agn']",https://twitter.com/BioStocks/status/1143470372857290752,False,,0,,,,,,,,[],,,,
1143466745287630849,1143466745287630849,2019-06-25 16:01:31 IST,2019-06-25,16:01:31,+0530,47678782,megtirrell,Meg Tirrell,,Whoa. WSJ: AbbVie Nears Deal to Buy Allergan for More Than $60 Billion $ABBV $AGN  https://t.co/tIoBVuGfCM,en,[],['https://www.wsj.com/articles/abbvie-nears-deal-to-buy-allergan-for-more-than-60-billion-11561458504'],[],8,69,107,[],"['abbv', 'agn']",https://twitter.com/megtirrell/status/1143466745287630849,False,,0,,,,,,,,[],,,,
1143466520938536962,1143466520938536962,2019-06-25 16:00:37 IST,2019-06-25,16:00:37,+0530,1469603575,qtrresearch,Quoth the Raven,,AbbVie $ABBV Nears Deal to Buy Allergan $AGN for More Than $60 Billion - WSJ/SI,en,[],[],[],2,2,7,[],"['abbv', 'agn']",https://twitter.com/QTRResearch/status/1143466520938536962,False,,0,,,,,,,,[],,,,
1143466074941337601,1143466074941337601,2019-06-25 15:58:51 IST,2019-06-25,15:58:51,+0530,3203314919,cararlombardo,Cara Lombardo,,.@WSJ SCOOP just hitting wire: AbbVie nearing a roughly $60B deal to buy Allergan $AGN $ABBV,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",[],[],0,10,21,[],"['agn', 'abbv']",https://twitter.com/CaraRLombardo/status/1143466074941337601,False,,0,,,,,,,,[],,,,
1143466050949918720,1143466050949918720,2019-06-25 15:58:45 IST,2019-06-25,15:58:45,+0530,84402174,street_insider,Streetinsider.com,,AbbVie $ABBV Nears Deal to Buy Allergan $AGN for More Than $60 Billion - WSJ,en,[],[],[],0,6,8,[],"['abbv', 'agn']",https://twitter.com/Street_Insider/status/1143466050949918720,False,,0,,,,,,,,[],,,,
1142473361244790784,1142473361244790784,2019-06-22 22:14:10 IST,2019-06-22,22:14:10,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,$ABBV AbbVie ...Has to break one way or the other at some point here soon.  https://t.co/WMZ3YuNAo9,en,[],[],['https://pbs.twimg.com/media/D9rhXKfWkAICkU1.jpg'],8,6,66,[],['abbv'],https://twitter.com/the_chart_life/status/1142473361244790784,False,,1,https://pbs.twimg.com/media/D9rhXKfWkAICkU1.jpg,,,,,,,[],,,,
1142096305579335680,1142096305579335680,2019-06-21 21:15:53 IST,2019-06-21,21:15:53,+0530,697732860741029888,edwinelmhirst,Edwin Elmhirst,,Abbvie proves the best at getting the most out of its workers  https://t.co/dp2XAX18ST $ABBV $BMY $SNY $AZN $CELG  https://t.co/seCfPewWN2,en,[],['https://www.evaluate.com/vantage/articles/data-insights/other-data/abbvie-proves-best-getting-most-out-its-workers'],"['https://pbs.twimg.com/media/D9mKTIzXsAUG7PJ.jpg', 'https://pbs.twimg.com/media/D9mKWV8WkAAp0sx.png']",3,10,8,[],"['abbv', 'bmy', 'sny', 'azn', 'celg']",https://twitter.com/EdwinElmhirst/status/1142096305579335680,False,,1,https://pbs.twimg.com/media/D9mKTIzXsAUG7PJ.jpg,,,,,,,[],,,,
1141776512439468032,1141776512439468032,2019-06-21 00:05:08 IST,2019-06-21,00:05:08,+0530,531892451,abbvie,AbbVie,,Today we declared a quarterly cash #dividend of $1.07 per share. Learn more:  https://t.co/icaeOvMFuk $ABBV  https://t.co/lRRaj8ILO2,en,[],['http://bit.ly/2FkLQ8g'],['https://pbs.twimg.com/media/D9hnr8XXkAAkB7b.jpg'],0,2,8,['dividend'],['abbv'],https://twitter.com/abbvie/status/1141776512439468032,False,,1,https://pbs.twimg.com/media/D9hnr8XXkAAkB7b.jpg,,,,,,,[],,,,
1130738888530649088,1130738888530649088,2019-05-21 13:05:33 IST,2019-05-21,13:05:33,+0530,401575573,dividendc2,dividendc2,,Mis TOP5 mejores compa√±√≠as - Healthcare -  Longevidad - largo plazo :  1: AbbVie Inc $ABBV  2: Amgen Inc $AMGN   3: Bristol-Myers Squibb Co $BMY  4: Medtronic PLC $MDT  5:  Biogen Inc $BIIB,ca,[],[],[],2,1,13,[],"['abbv', 'amgn', 'bmy', 'mdt', 'biib']",https://twitter.com/dividendc2/status/1130738888530649088,False,,0,,,,,,,,[],,,,
1129830568353574913,1129830568353574913,2019-05-19 00:56:13 IST,2019-05-19,00:56:13,+0530,401575573,dividendc2,dividendc2,,MY TOP5 best companies sector - INNOVATIVE HEALTHCARE -  long term:   1: Johnson &amp; Johnson $JNJ  2: Merck &amp; Co Inc $MRK  3: Pfizer Inc $PFE  4: Eli Lilly and Co $LLY   5: AbbVie Inc $ABBV,en,[],[],[],0,1,9,[],"['jnj', 'mrk', 'pfe', 'lly', 'abbv']",https://twitter.com/dividendc2/status/1129830568353574913,False,,0,,,,,,,,[],,,,
1129060216937603073,1129060216937603073,2019-05-16 21:55:07 IST,2019-05-16,21:55:07,+0530,531892451,abbvie,AbbVie,,We made it into the top 100 of @fortunemagazine‚Äôs #fortune500. Proud to be the only 6-year-old company on this prestigious list.  https://t.co/9M9w3tZMaw $ABBV,en,"[{'screen_name': 'fortunemagazine', 'name': 'fortune', 'id': '25053299'}]",['http://fortune.com/fortune500'],[],2,5,26,['fortune500'],['abbv'],https://twitter.com/abbvie/status/1129060216937603073,False,,0,,,,,,,,[],,,,
1128475795511488512,1128475795511488512,2019-05-15 07:12:50 IST,2019-05-15,07:12:50,+0530,102754598,johncendpts,John Carroll,,#2 -- $ABBV wins Boehringer Ingelheim flies the white flag as last holdout surrenders in war over a $20B AbbVie gold mine  https://t.co/CV2biGRAOK,en,[],['https://endpts.com/boehringer-ingelheim-flies-the-white-flag-as-last-holdout-surrenders-its-fight-over-a-humira-knockoff/'],[],0,4,9,[],['abbv'],https://twitter.com/JohnCendpts/status/1128475795511488512,False,,0,,,,,,,,[],,,,
1122816798607532033,1122816798607532033,2019-04-29 16:26:00 IST,2019-04-29,16:26:00,+0530,3426014292,semodough,dough,,BMO $ABBV Upgrading to Market Perform; More Bullish on Risa&amp;Upa; Many Uncertainties bearish ABBV thesis mostly materialized. we're now more bullish on Skyrizi&amp;Upa because we believe AbbVie can leverage its rebates to secure superior access in U.S. drive strong launches.,en,[],[],[],0,1,6,[],['abbv'],https://twitter.com/semodough/status/1122816798607532033,False,,0,,,,,,,,[],,,,
1121469604235304960,1121469604235304960,2019-04-25 23:12:44 IST,2019-04-25,23:12:44,+0530,976561004522991616,investaj,investaj,,Nytt bolag i üíº: ABBVIE $ABBV,sv,[],[],[],1,0,9,[],['abbv'],https://twitter.com/investaj/status/1121469604235304960,False,,0,,,,,,,,[],,,,
1121403518852771847,1121403518852771847,2019-04-25 18:50:08 IST,2019-04-25,18:50:08,+0530,531892451,abbvie,AbbVie,,We've grown our dividend by more than 50% in the past year. $ABBV #DividendAristocrat  https://t.co/rK2p9Q1FzS  https://t.co/sAtQ5qPzGI,en,[],['http://bit.ly/2UFhRwD'],['https://pbs.twimg.com/tweet_video_thumb/D5AGjHKW0AUQvFA.jpg'],14,4,15,['dividendaristocrat'],['abbv'],https://twitter.com/abbvie/status/1121403518852771847,False,,1,https://pbs.twimg.com/tweet_video_thumb/D5AGjHKW0AUQvFA.jpg,,,,,,,[],,,,
1121402248712654848,1121402248712654848,2019-04-25 18:45:05 IST,2019-04-25,18:45:05,+0530,531892451,abbvie,AbbVie,,We've continued to make significant investments in R&amp;D to build a robust pipeline. $ABBV  https://t.co/QHmdNFUyOb  https://t.co/NuAsAbL5dw,en,[],['http://bit.ly/2UFheDh'],['https://pbs.twimg.com/media/D5AFZuKW0AAFR3y.jpg'],12,4,13,[],['abbv'],https://twitter.com/abbvie/status/1121402248712654848,False,,1,https://pbs.twimg.com/media/D5AFZuKW0AAFR3y.jpg,,,,,,,[],,,,
1121386428741459968,1121386428741459968,2019-04-25 17:42:13 IST,2019-04-25,17:42:13,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q1'19 EPS(Non-GAAP) $2.14 ‰∫àÊÉ≥ +$0.07 Â£≤‰∏ä $7.83B (-1.3% Y/Y) ‰∫àÊÉ≥ +$20M  ‰∏ñÁïåÊúÄÂ§ßÂ£≤‰∏ä„ÇíË™á„Å£„Å¶„ÅÑ„ÅüÊ≤ªÁôÇËñ¨„Éí„É•„Éü„É©„ÅØ„Éê„Ç§„Ç™„Ç∑„Éü„É©„Éº„ÅßÊ∏õÈÄü„Åã„ÄÇ  Ê†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß+2.2%  https://t.co/KiLsOrhCVF  https://t.co/k0Fatzvudo,ja,[],['https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-first-quarter-2019-financial-results'],['https://pbs.twimg.com/media/D4_28PtUcAEbvCC.png'],0,5,29,[],[],https://twitter.com/KessanMan/status/1121386428741459968,False,,1,https://pbs.twimg.com/media/D4_28PtUcAEbvCC.png,,,,,,,[],,,,
1120359542192209920,1120359542192209920,2019-04-22 21:41:44 IST,2019-04-22,21:41:44,+0530,2379395095,therealpetrusko,petrusko,,Is a Beat in Store for AbbVie (ABBV) This Earnings Season?  https://t.co/R74CeznsCf via @YahooFinance,en,"[{'screen_name': 'yahoofinance', 'name': 'yahoo finance', 'id': '19546277'}]",['https://finance.yahoo.com/news/beat-store-abbvie-abbv-earnings-143302130.html?soc_src=community&soc_trk=tw'],[],0,0,10,[],[],https://twitter.com/therealpetrusko/status/1120359542192209920,False,,0,,,,,,,,[],,,,
1109750388176183296,1109750388176183296,2019-03-24 15:04:45 IST,2019-03-24,15:04:45,+0530,401575573,dividendc2,dividendc2,,"ABBVIE (ABBV) , 46 a√±os consecutivos de aumento de dividendos, AbbVie viene de un per√≠odo de varios a√±os de excelente crecimiento, gracias al √©xito masivo de su producto estrella Humira. Dividend Aristocrats, AbbVie es un gigante farmac√©utico global.  243 ETF con exposici√≥n .  https://t.co/ScS1wASjJV",es,[],[],['https://pbs.twimg.com/media/D2agAIAXgAAPSNN.png'],1,3,18,[],[],https://twitter.com/dividendc2/status/1109750388176183296,False,,1,https://pbs.twimg.com/media/D2agAIAXgAAPSNN.png,,,,,,,[],,,,
1108409931542265857,1108409931542265857,2019-03-20 22:18:15 IST,2019-03-20,22:18:15,+0530,13171622,pharmalot,pharmalot,,AbbVie is sued for using Humira patent deals to block competition in the U.S... read why this is a first-of-its-kind lawsuit..  https://t.co/ydZyymXk2l #pharma #patents #drugprice $ABBV $PFE $NVS $MYL $AMGN $MNTA,en,[],['https://www.statnews.com/pharmalot/2019/03/20/abbvie-humira-patents-antitrust/'],[],0,9,6,"['pharma', 'patents', 'drugprice']","['abbv', 'pfe', 'nvs', 'myl', 'amgn', 'mnta']",https://twitter.com/pharmalot/status/1108409931542265857,False,,0,,,,,,,,[],,,,
1107996487659737090,1107996487659737090,2019-03-19 18:55:22 IST,2019-03-19,18:55:22,+0530,102754598,johncendpts,John Carroll,,"$ABBV $RHHBY Roche, AbbVie slam the brakes on myeloma studies of star drug Venclexta after researchers flag higher risk of death  https://t.co/49fPPGZ6EG",en,[],['https://endpts.com/roche-abbvie-slam-the-brakes-on-myeloma-studies-of-star-drug-venclexta-after-researchers-flag-higher-risk-of-death/'],[],1,6,11,[],"['abbv', 'rhhby']",https://twitter.com/JohnCendpts/status/1107996487659737090,False,,0,,,,,,,,[],,,,
1103276635019771904,1103276635019771904,2019-03-06 18:20:22 IST,2019-03-06,18:20:22,+0530,1003002933376700422,aoifemlbrennan,Aoifemlbrennan,,Patients with IBD need better treatment options. Delighted to be working with AbbVie $ABBV to advance our collaboration. @synlogic_tx $SYBX #IBD  https://t.co/kUGEw980bA,en,"[{'screen_name': 'synlogic_tx', 'name': 'synlogic, inc.', 'id': '2788389948'}]",['https://www.businesswire.com/news/home/20190306005188/en/'],[],2,6,35,['ibd'],"['abbv', 'sybx']",https://twitter.com/aoifemlbrennan/status/1103276635019771904,False,,0,,,,,,,,[],,,,
1100391305757233152,1100391305757233152,2019-02-26 19:15:06 IST,2019-02-26,19:15:06,+0530,25998862,drugchannels,Adam J. Fein,,"Must watch TV! Today at 10:15 AM, @SenateFinance hearing on ""Drug Pricing in America"" with @abbvie $ABBV, @AstraZeneca $AZN, @bmsnews $BMS, @JanssenUS $JNJ, @Merck $MRK, @pfizer $PFE, and @SanofiUS $SNY.  https://t.co/jUH9TJ5rLV  P.S. Over/under on use of ""skyrocketing"" = 42  https://t.co/uxBL775ztK",en,"[{'screen_name': 'senatefinance', 'name': 'senate finance cmte', 'id': '628709039'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'astrazeneca', 'name': 'astrazeneca', 'id': '62465691'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'janssenus', 'name': 'janssenus', 'id': '256182836'}, {'screen_name': 'merck', 'name': 'merck', 'id': '35961145'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sanofius', 'name': 'sanofi us', 'id': '183033795'}]",['https://drugch.nl/2Vic8NR'],['https://pbs.twimg.com/media/D0VgD50XQAMNf8R.jpg'],1,3,11,[],"['abbv', 'azn', 'bms', 'jnj', 'mrk', 'pfe', 'sny']",https://twitter.com/DrugChannels/status/1100391305757233152,False,,1,https://pbs.twimg.com/media/D0VgD50XQAMNf8R.jpg,,,,,,,[],,,,
1098960320993939457,1098960320993939457,2019-02-22 20:28:52 IST,2019-02-22,20:28:52,+0530,102754598,johncendpts,John Carroll,,"AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash $VYGR $ABBV @NatalieGrover   https://t.co/FD7J4lcfLA",en,"[{'screen_name': 'nataliegrover', 'name': 'natalie grover', 'id': '119475889'}]",['https://endpts.com/abbvie-hands-voyager-a-mega-billions-gene-therapy-deal-with-310m-in-near-term-cash/'],[],1,8,11,[],"['vygr', 'abbv']",https://twitter.com/JohnCendpts/status/1098960320993939457,False,,0,,,,,,,,[],,,,
1098946933664698368,1098946933664698368,2019-02-22 19:35:41 IST,2019-02-22,19:35:41,+0530,35789155,fwpharma,FirstWord Pharma,,"Following deal focused on Alzheimer's disease, AbbVie, Voyager Therapeutics expand collaboration to Parkinson's disease  https://t.co/hpAWDFenVH $ABBV $VYGR",en,[],['https://www.firstwordpharma.com/node/1626464'],[],0,3,5,[],"['abbv', 'vygr']",https://twitter.com/fwpharma/status/1098946933664698368,False,,0,,,,,,,,[],,,,
1098933192223064064,1098933192223064064,2019-02-22 18:41:04 IST,2019-02-22,18:41:04,+0530,531892451,abbvie,AbbVie,,LATEST NEWS: We just announced a new collaboration w/ @VoyagerTx focused on developing potential treatments for Parkinson‚Äôs disease. Learn more:  https://t.co/6u21Slegqk $ABBV  https://t.co/TduafQUGDe,en,"[{'screen_name': 'voyagertx', 'name': 'voyager therapeutics', 'id': '956234721033375744'}]",['http://bit.ly/2E3z38H'],['https://pbs.twimg.com/media/D0Ax6fVXQAAWrTh.png'],0,6,10,[],['abbv'],https://twitter.com/abbvie/status/1098933192223064064,False,,1,https://pbs.twimg.com/media/D0Ax6fVXQAAWrTh.png,,,,,,,[],,,,
1096798277922680834,1096798277922680834,2019-02-16 21:17:41 IST,2019-02-16,21:17:41,+0530,2499229069,dvdnddiplomats,Dividend Diplomats,,Bert's latest purchase into big #Pharmaceutical company - AbbVie Inc $ABBV for the high #Dividend yield!  https://t.co/4RxfpBlrT6,en,[],['https://www.dividenddiplomats.com/berts-recent-purchase-abbvie-abbv/'],[],0,1,6,"['pharmaceutical', 'dividend']",['abbv'],https://twitter.com/DvdndDiplomats/status/1096798277922680834,False,,0,,,,,,,,[],,,,
1095412291602972682,1095412291602972682,2019-02-13 01:30:16 IST,2019-02-13,01:30:16,+0530,531892451,abbvie,AbbVie,,Learn about our recently announced partnership w/ Teneobio to develop a new treatment for #multiplemyleoma:  https://t.co/kb1WrWI7Kw $ABBV  https://t.co/QzIwHWy7Aj,en,[],['http://bit.ly/2Ib58Ra'],['https://pbs.twimg.com/media/DzOvrDaXgAICBaw.jpg'],0,6,14,['multiplemyleoma'],['abbv'],https://twitter.com/abbvie/status/1095412291602972682,False,,1,https://pbs.twimg.com/media/DzOvrDaXgAICBaw.jpg,,,,,,,[],,,,
1093514900339679234,1093514900339679234,2019-02-07 19:50:43 IST,2019-02-07,19:50:43,+0530,19324828,twhitfill,Travis Whitfill MPH,,"Really impressed with @synlogic_tx with their engineered microbes, paving the way for other engineered microbe-based products. They‚Äôre partnering with @abbvie   $SYBX $ABBV  #microbiome #MBCongress2019  https://t.co/a1HogGOyZb",en,"[{'screen_name': 'synlogic_tx', 'name': 'synlogic, inc.', 'id': '2788389948'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",[],['https://pbs.twimg.com/media/DyzyAJNUwAE0lAM.jpg'],0,2,4,"['microbiome', 'mbcongress2019']","['sybx', 'abbv']",https://twitter.com/twhitfill/status/1093514900339679234,False,,1,https://pbs.twimg.com/media/DyzyAJNUwAE0lAM.jpg,,,,,,,[],,,,
1090270206671245314,1090270206671245314,2019-01-29 20:57:28 IST,2019-01-29,20:57:28,+0530,1476783300,dgiandr,DGI&R,,Bought more AbbVie Inc. $ABBV today at $78.02. A cheap stock with a 5.5% dividend yield that I expect to grow. Still risky though because of their reliance on Humira.,en,[],[],[],1,0,7,[],['abbv'],https://twitter.com/DGIandR/status/1090270206671245314,False,,0,,,,,,,,[],,,,
1089970153209688067,1089970153209688067,2019-01-29 01:05:09 IST,2019-01-29,01:05:09,+0530,132996026,mrdividendo,Mr. Dividendo,,"Aprovechamos las rebajas de final de mes para hacer alguna compra mensual pero no ser√°n las √∫nicas de Enero. Hoy ha tocado a√±adir al holding: AbbVie NYSE:ABBV, Exxon Mobile NYSE:XOM, Westpac Banking NYSE:WBK y Wells Fargo NYSE:WFC. ¬øQu√© os parecen?",es,[],[],[],5,1,23,[],[],https://twitter.com/mrdividendo/status/1089970153209688067,False,,0,,,,,,,,[],,,,
1089906276816089090,1089906276816089090,2019-01-28 20:51:20 IST,2019-01-28,20:51:20,+0530,472426245,adamgalas1,Dividend Sensei,,$ABBV - 3 Reasons I Just Tripled Down On AbbVie  https://t.co/1jvMR3wIml,en,[],['https://seekingalpha.com/article/4235895-3-reasons-just-tripled-abbvie?source=tweet'],[],1,2,3,[],['abbv'],https://twitter.com/adamgalas1/status/1089906276816089090,False,,0,,,,,,,,[],,,,
1089852824480112640,1089852824480112640,2019-01-28 17:18:56 IST,2019-01-28,17:18:56,+0530,3426014292,semodough,dough,,"BMO $ABBV Humira has peaked at $20Bn&amp;should decline going forward. AbbVie entering a period of slower revenue growth (flat in 2019, 2018-2022 CAGR of ~3-4%), followed by decline after 2022. ABBV's ~5% dividend yield&amp;low P/E-multiple are enticing, in 2019,expect uncertainty",en,[],[],[],1,1,8,[],['abbv'],https://twitter.com/semodough/status/1089852824480112640,False,,0,,,,,,,,[],,,,
1088811208159973380,1088811208159973380,2019-01-25 20:19:55 IST,2019-01-25,20:19:55,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q4 EPS(Non-GAAP) $1.90 ‰∫àÊÉ≥ -$0.04 Â£≤‰∏ä $8.31B (+7.4% Y/Y) ‰∫àÊÉ≥ -$60M  2017Âπ¥‰∏ñÁïå„ÅßÊúÄ„ÇÇÂ£≤„Çå„ÅüËñ¨„Éí„É•„Éü„É©„ÅÆ‰ºöÁ§æ  Ê†™‰æ°-6.6%  https://t.co/XOUyYodOwd  https://t.co/ag18CRM08c,ja,[],['https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2018-financial'],['https://pbs.twimg.com/media/Dxw7__wWwAYmhT1.jpg'],0,3,22,[],[],https://twitter.com/KessanMan/status/1088811208159973380,False,,1,https://pbs.twimg.com/media/Dxw7__wWwAYmhT1.jpg,,,,,,,[],,,,
1088803693519126528,1088803693519126528,2019-01-25 19:50:04 IST,2019-01-25,19:50:04,+0530,531892451,abbvie,AbbVie,,We have grown our dividend significantly since inception in 2013. $ABBV  https://t.co/05ZGlMVaDy,en,[],[],['https://pbs.twimg.com/media/Dxw1MFRWoAU12sw.jpg'],1,5,18,[],['abbv'],https://twitter.com/abbvie/status/1088803693519126528,False,,1,https://pbs.twimg.com/media/Dxw1MFRWoAU12sw.jpg,,,,,,,[],,,,
1088799926929313792,1088799926929313792,2019-01-25 19:35:06 IST,2019-01-25,19:35:06,+0530,531892451,abbvie,AbbVie,,"We continue to make significant, strategic investments in R&amp;D to advance our pipeline. $ABBV  https://t.co/reS8Z4xG58",en,[],[],['https://pbs.twimg.com/media/Dxwxw1PXgAUmi70.jpg'],2,5,27,[],['abbv'],https://twitter.com/abbvie/status/1088799926929313792,False,,1,https://pbs.twimg.com/media/Dxwxw1PXgAUmi70.jpg,,,,,,,[],,,,
1084879260651843586,1084860377828126720,2019-01-14 23:55:46 IST,2019-01-14,23:55:46,+0530,42782695,berkeleyjr,Berkeley Lovelace,,The 12 companies that the panel requested information from:  AbbVie $ABBV Amgen $AMGN AstraZeneca $AZN Celgene $CELG Eli Lilly $LLY Johnson &amp; Johnson $JNJ Mallinckrodt $MNK Novartis $NVS Novo Nordisk $NVO Pfizer $PFE Sanofi $SNY Teva Pharmaceuticals $TEVA,en,[],[],[],1,3,6,[],"['abbv', 'amgn', 'azn', 'celg', 'lly', 'jnj', 'mnk', 'nvs', 'nvo', 'pfe', 'sny', 'teva']",https://twitter.com/BerkeleyJr/status/1084879260651843586,False,,0,,,,,,,,[],,,,
1083044578222051328,1083044578222051328,2019-01-09 22:25:24 IST,2019-01-09,22:25:24,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @GileadSciences @abbvie @pfizer @Celgene @Roche  Sangamo will have HIV clinical data readout within 2 months.  Are you interested in an HIV Cure option? @SangamoTx wants to partner this pipeline.  https://t.co/u0bn7x2bvO  $SGMO $GILD $ABBV $PFE $CELG #JPM19,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",['https://clinicaltrials.gov/ct2/show/NCT02500849'],[],0,2,13,['jpm19'],"['sgmo', 'gild', 'abbv', 'pfe', 'celg']",https://twitter.com/Biotech2050/status/1083044578222051328,False,,0,,,,,,,,[],,,,
1075039063894355968,1075039063894355968,2018-12-18 20:14:20 IST,2018-12-18,20:14:20,+0530,872519322077470721,tdanetwork,TD Ameritrade Network,,"Some big names are getting hit hard:  - Netflix $NFLX  - Facebook $FB  - DowDuPont $DWDP  - Citigroup $C  - AbbVie $ABBV  But is the market #selloff overdone? On #MorningTradeLive, @NPetallides and @OJRenick take a look at the big picture:  https://t.co/SNXglUKpnM",en,"[{'screen_name': 'npetallides', 'name': 'nicole petallides', 'id': '2353958539'}, {'screen_name': 'ojrenick', 'name': 'oliver renick', 'id': '1580555131'}]",[],[],1,9,27,"['selloff', 'morningtradelive']","['nflx', 'fb', 'dwdp', 'c', 'abbv']",https://twitter.com/TDANetwork/status/1075039063894355968,False,,1,https://pbs.twimg.com/media/DutL3UPW0AAoszQ.jpg,,,,,,,[],,,,
1073276721527435265,1073276721527435265,2018-12-13 23:31:25 IST,2018-12-13,23:31:25,+0530,801116888,cfromhertz,Christian Fromhertz,,*ABBVIE REPORTS $5B BOOST TO STOCK BUYBACK PROGRAM $ABBV,en,[],[],[],0,2,12,[],['abbv'],https://twitter.com/cfromhertz/status/1073276721527435265,False,,0,,,,,,,,[],,,,
1070431520823873538,1070431520823873538,2018-12-06 03:05:36 IST,2018-12-06,03:05:36,+0530,102754598,johncendpts,John Carroll,,AbbVie‚Äôs $10B Rova-T cancer drug program takes a sudden turn toward the cliff $ABBV  https://t.co/zpiYWOr6Vf,en,[],['https://endpts.com/abbvies-10b-rova-t-cancer-drug-program-takes-a-sudden-turn-toward-the-cliff/'],[],0,4,7,[],['abbv'],https://twitter.com/JohnCendpts/status/1070431520823873538,False,,0,,,,,,,,[],,,,
1070431511256723456,1070431511256723456,2018-12-06 03:05:34 IST,2018-12-06,03:05:34,+0530,3460109487,endpts,Endpoints News,,The Rova-T problem at AbbVie may be headed toward a full-fledged disaster. $ABBV  https://t.co/9GCst0vity,en,[],['https://endpts.com/abbvies-10b-rova-t-cancer-drug-program-takes-a-sudden-turn-toward-the-cliff/'],[],0,1,8,[],['abbv'],https://twitter.com/endpts/status/1070431511256723456,False,,0,,,,,,,,[],,,,
1068532232564944897,1068532232564944897,2018-11-30 21:18:31 IST,2018-11-30,21:18:31,+0530,15563814,loftus,Peter Loftus,,"Pfizer becomes 7th drugmaker to reach deal with AbbVie to sell biosimilar version of Humira, agreeing to wait until 2023 to launch in U.S. $PFE $ABBV",en,[],[],[],4,18,26,[],"['pfe', 'abbv']",https://twitter.com/Loftus/status/1068532232564944897,False,,0,,,,,,,,[],,,,
1065712808350924801,1065712808350924801,2018-11-23 02:35:08 IST,2018-11-23,02:35:08,+0530,15568127,themotleyfool,The Motley Fool,,"They aren‚Äôt exactly on Black Friday sales, but shares of AbbVie, 3M  and Netflix could be gifts that keep on giving. $ABBV $MMM $NFLX  https://t.co/kxQYa3LRIV",en,[],['https://www.fool.com/investing/2018/11/20/3-top-large-cap-stocks-to-buy-in-november.aspx'],[],1,4,12,[],"['abbv', 'mmm', 'nflx']",https://twitter.com/themotleyfool/status/1065712808350924801,False,,0,,,,,,,,[],,,,
1064165835399458816,1064165835399458816,2018-11-18 20:08:01 IST,2018-11-18,20:08:01,+0530,3460109487,endpts,Endpoints News,,AbbVie touts promising PhIII data for Orilissa as execs line up their second pitch and rivals lay in wait  https://t.co/6al6MWXiXd $ABBV,en,[],['https://endpts.com/abbvie-touts-promising-phiii-data-for-orilissa-as-execs-line-up-their-second-pitch-and-rivals-lay-in-wait/'],[],0,1,7,[],['abbv'],https://twitter.com/endpts/status/1064165835399458816,False,,0,,,,,,,,[],,,,
1060554246846902273,1060554246846902273,2018-11-08 20:56:51 IST,2018-11-08,20:56:51,+0530,102754598,johncendpts,John Carroll,,AbbVie hatches plans for a major new R&amp;D hub close to its partners in Bay Area‚Äôs buzzy Oyster Point $ABBV @AmberTongPW   https://t.co/EUHZ17qHUr,en,"[{'screen_name': 'ambertongpw', 'name': 'amber tong', 'id': '746441781588426752'}]",['https://endpts.com/abbvie-hatches-plans-for-a-major-new-rd-hub-close-to-its-partners-in-bay-areas-buzzy-oyster-point/'],[],0,5,9,[],['abbv'],https://twitter.com/JohnCendpts/status/1060554246846902273,False,,0,,,,,,,,[],,,,
1060346445784596480,1060346445784596480,2018-11-08 07:11:07 IST,2018-11-08,07:11:07,+0530,2985017187,7innovator,Simon Erickson,,"AbbVie $ABBV is a huge opportunity at $87. Humira IP has risks, but still growing @ 10% globally. Imbruvica up 41% (!) and a stocked IO pipeline right behind it. Incredibly shareholder-friendly: mgmt has raised the dividend 168% in 5 yrs. This is a long term winner. #SEconviction",en,[],[],[],0,1,7,['seconviction'],['abbv'],https://twitter.com/7Innovator/status/1060346445784596480,False,,0,,,,,,,,[],,,,
1058349822330064897,1058349822330064897,2018-11-02 18:57:15 IST,2018-11-02,18:57:15,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q3 EPS $2.14 ‰∫àÊÉ≥ +$0.13 Â£≤‰∏ä $8.24B (+17.7% Y/Y) ‰∫àÊÉ≥ +$20M  Ê†™‰æ°„ÅØÊôÇÈñìÂ§ñ„Åß+5%  2017Âπ¥„Å´‰∏ñÁïå„ÅßÊúÄ„ÇÇÂ£≤„Çå„ÅüËñ¨ Humira(„Éí„É•„Éü„É©)„ÅÆ‰ºöÁ§æ  PDF:  https://t.co/CaZwYYs8Je  https://t.co/qg90DhJVWp,ja,[],['https://investors.abbvie.com/static-files/184e032f-41e4-4324-a0c9-6683bbef9781'],['https://pbs.twimg.com/media/DrADe6GU8AI0DM9.jpg'],1,4,13,[],[],https://twitter.com/KessanMan/status/1058349822330064897,False,,1,https://pbs.twimg.com/media/DrADe6GU8AI0DM9.jpg,,,,,,,[],,,,
1058348028812255233,1058348028812255233,2018-11-02 18:50:07 IST,2018-11-02,18:50:07,+0530,531892451,abbvie,AbbVie,,We're raising our quarterly dividend for the 2nd time this year. $ABBV  https://t.co/nKIuMT55dD,en,[],[],['https://pbs.twimg.com/tweet_video_thumb/DrAB6evXcAElYEm.jpg'],0,2,15,[],['abbv'],https://twitter.com/abbvie/status/1058348028812255233,False,,1,https://pbs.twimg.com/tweet_video_thumb/DrAB6evXcAElYEm.jpg,,,,,,,[],,,,
1058346759527772162,1058346759527772162,2018-11-02 18:45:05 IST,2018-11-02,18:45:05,+0530,531892451,abbvie,AbbVie,,We made significant investments in R&amp;D to advance and accelerate our pipeline programs in Q3. $ABBV  https://t.co/XEMSa3I79I,en,[],[],['https://pbs.twimg.com/media/DrAAxLwWwAAvVLD.jpg'],0,2,10,[],['abbv'],https://twitter.com/abbvie/status/1058346759527772162,False,,1,https://pbs.twimg.com/media/DrAAxLwWwAAvVLD.jpg,,,,,,,[],,,,
1058047644055019521,1058047644055019521,2018-11-01 22:56:30 IST,2018-11-01,22:56:30,+0530,102094857,adamfeuerstein,Adam Feuerstein,,AbbVie offers a ‚Äòhuge‚Äô discount on Humira to fend off European rivals  https://t.co/cHkLLqKsOn via @pharmalot $ABBV,en,"[{'screen_name': 'pharmalot', 'name': 'pharmalot', 'id': '13171622'}]",['https://www.statnews.com/pharmalot/2018/11/01/abbvie-humira-biosimilars-prices/'],[],1,3,9,[],['abbv'],https://twitter.com/adamfeuerstein/status/1058047644055019521,False,,0,,,,,,,,[],,,,
1055192476733136896,1055192476733136896,2018-10-25 01:51:05 IST,2018-10-25,01:51:05,+0530,531892451,abbvie,AbbVie,,Read our latest news: $ABBV will assume full responsibility of cystic fibrosis research program to discover and develop new therapies to treat #CF  https://t.co/Sm9zQyGJNE  https://t.co/0qwDyVyDRL,en,[],['http://bit.ly/2POrEia'],['https://pbs.twimg.com/media/DqTL9w5X4AU6x5y.jpg'],3,2,19,['cf'],['abbv'],https://twitter.com/abbvie/status/1055192476733136896,False,,1,https://pbs.twimg.com/media/DqTL9w5X4AU6x5y.jpg,,,,,,,[],,,,
1055188762341318656,1055188762341318656,2018-10-25 01:36:20 IST,2018-10-25,01:36:20,+0530,126416038,odibro,Odi Bruckman,,$GLPG $ABBV announce a restructuring of their cystic fibrosis alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF   https://t.co/I2gA4FM8ES,en,[],['https://globenewswire.com/news-release/2018/10/24/1626590/0/en/Galapagos-and-AbbVie-restructure-CF-collaboration.html'],[],0,5,7,[],"['glpg', 'abbv']",https://twitter.com/odibro/status/1055188762341318656,False,,0,,,,,,,,[],,,,
1054420992448024576,1054420992448024576,2018-10-22 22:45:29 IST,2018-10-22,22:45:29,+0530,926793032,firsttomarkets,FirstToMarkets,,AbbVie Inc  Reiterated Rating by SunTrust Equitable (Ranked 15th) to Buy with $135PT $ABBV #ABBV  https://t.co/kaP28qlf1p,en,[],['http://www.firsttomarkets.com/FTMMobile/#/stock/1881'],[],0,0,0,['abbv'],['abbv'],https://twitter.com/firsttomarkets/status/1054420992448024576,False,,0,,,,,,,,[],,,,
1053680101114765313,1053680101114765313,2018-10-20 21:41:27 IST,2018-10-20,21:41:27,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,$ABBV Abbvie ...Watching to see if we move lower from the descending triangle.  https://t.co/xQnbYHuBWj,en,[],[],['https://pbs.twimg.com/media/Dp9sc0UXQAAk_iN.jpg'],1,1,7,[],['abbv'],https://twitter.com/the_chart_life/status/1053680101114765313,False,,1,https://pbs.twimg.com/media/Dp9sc0UXQAAk_iN.jpg,,,,,,,[],,,,
1052897102714589184,1052897102714589184,2018-10-18 17:50:05 IST,2018-10-18,17:50:05,+0530,531892451,abbvie,AbbVie,,"Today we announced a collaboration with Morphic Therapeutic, targeting fibrotic diseases ‚Äì a major area of medical need. Learn more:  https://t.co/QNo7NXESQE $ABBV  https://t.co/IUDCzmAcoE",en,[],['http://bit.ly/2CVoCWC'],['https://pbs.twimg.com/media/DpykVXXXcAAK8l6.jpg'],1,7,25,[],['abbv'],https://twitter.com/abbvie/status/1052897102714589184,False,,1,https://pbs.twimg.com/media/DpykVXXXcAAK8l6.jpg,,,,,,,[],,,,
1052892339440631808,1052892339440631808,2018-10-18 17:31:10 IST,2018-10-18,17:31:10,+0530,102754598,johncendpts,John Carroll,,AbbVie frontloads Morphic fibrosis development deal with $100M in cash $ABBV  https://t.co/e3yQm7YMP1,en,[],['https://endpts.com/abbvie-frontloads-morphic-fibrosis-development-deal-with-100m-in-cash/'],[],0,3,15,[],['abbv'],https://twitter.com/JohnCendpts/status/1052892339440631808,False,,0,,,,,,,,[],,,,
1051512458379190272,1051512458379190272,2018-10-14 22:08:00 IST,2018-10-14,22:08:00,+0530,3460109487,endpts,Endpoints News,,AbbVie staves off another US Humira knockoff to 2023 as European launch looms  https://t.co/1SbfpzjupO $ABBV,en,[],['https://endpts.com/abbvie-staves-off-another-us-humira-knockoff-to-2023-as-european-launch-looms/'],[],0,0,4,[],['abbv'],https://twitter.com/endpts/status/1051512458379190272,False,,0,,,,,,,,[],,,,
1032210455757025280,1032210455757025280,2018-08-22 15:48:44 IST,2018-08-22,15:48:44,+0530,102754598,johncendpts,John Carroll,,"$60M in, AbbVie is triggering a $625M-plus plan to develop a new immuno-oncology drug that is going after GARP $ABBV $ARGX  https://t.co/6D9iXpaQfD",en,[],['https://endpts.com/60m-in-abbvie-is-triggering-a-625m-plus-plan-to-develop-a-new-immuno-oncology-drug-that-is-going-after-garp/'],[],0,6,12,[],"['abbv', 'argx']",https://twitter.com/JohnCendpts/status/1032210455757025280,False,,0,,,,,,,,[],,,,
1027351323178684416,1027351323178684416,2018-08-09 06:00:17 IST,2018-08-09,06:00:17,+0530,15568127,themotleyfool,The Motley Fool,,"There are strong reasons to expect the growth days will return for AbbVie, Pfizer, and Welltower. Meantime, their yields are healthy all by themselves. $ABBV $PFE $WELL  https://t.co/9nI9o35xEE",en,[],['https://www.fool.com/investing/2018/08/07/get-paid-while-you-wait-3-top-dividend-stocks-in-h.aspx'],[],0,10,23,[],"['abbv', 'pfe', 'well']",https://twitter.com/themotleyfool/status/1027351323178684416,False,,0,,,,,,,,[],,,,
1022815968731353089,1022815968731353089,2018-07-27 17:38:24 IST,2018-07-27,17:38:24,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q2 EPS $2.00 ‰∫àÊÉ≥ +$0.03 Â£≤‰∏ä $8.28B (+19.3% Y/Y) ‰∫àÊÉ≥ +$70M  2017Âπ¥„ÄÅ‰∏ñÁïå„ÅßÊúÄ„ÇÇÂ£≤„Çå„ÅüËñ¨„ÅØAbbVie„ÅÆHumira(„Éí„É•„Éü„É©)  https://t.co/P9w0Bp3UlF  https://t.co/PQ1KTHnBA4,ja,[],['http://investors.abbvie.com'],['https://pbs.twimg.com/media/DjHEsFeU4AA0kVg.jpg'],0,3,17,[],[],https://twitter.com/KessanMan/status/1022815968731353089,False,,1,https://pbs.twimg.com/media/DjHEsFeU4AA0kVg.jpg,,,,,,,[],,,,
1021754796573949952,1021754796573949952,2018-07-24 19:21:41 IST,2018-07-24,19:21:41,+0530,15563814,loftus,Peter Loftus,,"FDA approves AbbVie's new treatment for endometriosis, Orilissa, will cost about $850 a month $ABBV  https://t.co/Q2QbsFLTY3",en,[],['https://news.abbvie.com/news/abbvie-receives-us-fda-approval-orilissa-elagolix-for-management-moderate-to-severe-pain-associated-with-endometriosis.htm'],[],1,5,6,[],['abbv'],https://twitter.com/Loftus/status/1021754796573949952,False,,0,,,,,,,,[],,,,
1019968446648475649,1019968446648475649,2018-07-19 21:03:22 IST,2018-07-19,21:03:22,+0530,2985017187,7innovator,Simon Erickson,,"I bought more AbbVie $ABBV on today's unjustified dip. This is Big Pharma's leader  (#1 or #2) in Rev growth, EPS growth, and Total Return for the past 1, 3, and 5 yr periods and their pipeline is strong. Citron calling it Dirty Money is downright ignorant  https://t.co/7hBfdz1AZ5",en,[],['https://www.marketwatch.com/story/abbvie-shares-drop-55-after-short-seller-citron-calls-it-next-great-drug-short-2018-07-19'],[],2,1,8,[],['abbv'],https://twitter.com/7Innovator/status/1019968446648475649,False,,0,,,,,,,,[],,,,
1019941724192325634,1019941724192325634,2018-07-19 19:17:11 IST,2018-07-19,19:17:11,+0530,236953420,citronresearch,Citron Research,,"$ABBV the next great drug short. TGT price $60  Gottlieb's comments for biosimilars and the removal of safe harbor is a DIRECT hit on Abbvie's abuse of Humira. Citron to release a series of reports detailing the Dirty Money. POTUS, AMZN, and now FDA on the case $60 in 12 months",en,[],[],[],44,47,113,[],['abbv'],https://twitter.com/CitronResearch/status/1019941724192325634,False,,0,,,,,,,,[],,,,
1015991126170521605,1015991126170521605,2018-07-08 21:38:55 IST,2018-07-08,21:38:55,+0530,3426014292,semodough,dough,,HCV Scripts Since 2016 (AbbVie‚Äôs Mavyret in Green) $ENTA $GILD $ABBV #HCV  https://t.co/AadSHtRGCG,en,[],[],['https://pbs.twimg.com/media/DhmGiY-VMAAy40W.jpg'],1,4,16,['hcv'],"['enta', 'gild', 'abbv']",https://twitter.com/semodough/status/1015991126170521605,False,,1,https://pbs.twimg.com/media/DhmGiY-VMAAy40W.jpg,,,,,,,[],,,,
1012440246351532032,1012440246351532032,2018-06-29 02:28:59 IST,2018-06-29,02:28:59,+0530,1705420616,btlipschultz,Bailey Lipschultz,,Trading in Galapagos to resume at 5:05pm ET after news that AbbVie will not to proceed with second triple combo in Cystic Fibrosis. Vertex up 9.1% post-market. Oh and Acceleron and Celgene's trial hit their primary endpoints. What a day to cover health stocks $glpg $abbv $vrtx,en,[],[],[],0,0,5,[],"['glpg', 'abbv', 'vrtx']",https://twitter.com/BTLipschultz/status/1012440246351532032,False,,0,,,,,,,,[],,,,
1011599786888359936,1011599786888359936,2018-06-26 18:49:18 IST,2018-06-26,18:49:18,+0530,3460109487,endpts,Endpoints News,,"A monster discovery deal between AbbVie and Google‚Äôs Calico gets a new lease on the lab, with $1B more to back aging research  https://t.co/cCr6dRgkL1 $ABBV",en,[],['https://endpts.com/a-monster-discovery-deal-between-abbvie-and-googles-calico-gets-a-new-lease-on-the-lab-with-1b-more-to-back-aging-research/'],[],0,1,6,[],['abbv'],https://twitter.com/endpts/status/1011599786888359936,False,,0,,,,,,,,[],,,,
1011584888863117312,1011584888863117312,2018-06-26 17:50:06 IST,2018-06-26,17:50:06,+0530,531892451,abbvie,AbbVie,,"#Breaking: We are extending our collaboration with Calico, an Alphabet-backed life sciences company focused on aging research. Learn more:  https://t.co/9tXhGh7vz6 $ABBV  https://t.co/RJbVrZvrHo",en,[],['http://bit.ly/2lBhJik'],['https://pbs.twimg.com/media/DgnfGEuU8AAd_GB.jpg'],0,19,43,['breaking'],['abbv'],https://twitter.com/abbvie/status/1011584888863117312,False,,1,https://pbs.twimg.com/media/DgnfGEuU8AAd_GB.jpg,,,,,,,[],,,,
1011580120598007813,1011580120598007813,2018-06-26 17:31:09 IST,2018-06-26,17:31:09,+0530,102754598,johncendpts,John Carroll,,"A monster discovery deal between AbbVie and Google‚Äôs Calico gets a new lease on the lab, with $1B more to back aging research $ABBV  https://t.co/wu49bcz9tD",en,[],['https://endpts.com/a-monster-discovery-deal-between-abbvie-and-googles-calico-gets-a-new-lease-on-the-lab-with-1b-more-to-back-aging-research/'],[],1,4,13,[],['abbv'],https://twitter.com/JohnCendpts/status/1011580120598007813,False,,0,,,,,,,,[],,,,
1011207394788040704,1011207394788040704,2018-06-25 16:50:04 IST,2018-06-25,16:50:04,+0530,531892451,abbvie,AbbVie,,Just announced: a collaboration w/ Calibr and @scrippsresearch to develop new T-cell therapies aimed primarily at cancer. Learn more:  https://t.co/aJ5yqsKLPh $ABBV  https://t.co/EfEQvlPzol,en,"[{'screen_name': 'scrippsresearch', 'name': 'scripps research', 'id': '805004869'}]",['http://bit.ly/2tnZNMH'],['https://pbs.twimg.com/media/DgiHxAoWsAAaWdU.jpg'],0,8,28,[],['abbv'],https://twitter.com/abbvie/status/1011207394788040704,False,,1,https://pbs.twimg.com/media/DgiHxAoWsAAaWdU.jpg,,,,,,,[],,,,
1007397060851662849,1007397060851662849,2018-06-15 04:29:10 IST,2018-06-15,04:29:10,+0530,531892451,abbvie,AbbVie,,"Today, we declared a quarterly dividend of 96 cents per share. Learn more:  https://t.co/lWQPCIFCHY  $ABBV #DividendAristocrat  https://t.co/PhLriZHMDd",en,[],['http://bit.ly/2JOOqDw'],['https://pbs.twimg.com/media/Dfr-SZiXcAAvZu7.jpg'],0,1,9,['dividendaristocrat'],['abbv'],https://twitter.com/abbvie/status/1007397060851662849,False,,1,https://pbs.twimg.com/media/Dfr-SZiXcAAvZu7.jpg,,,,,,,[],,,,
1006256283127726080,1006256283127726080,2018-06-12 00:56:07 IST,2018-06-12,00:56:07,+0530,73845366,hmkyale,Harlan Krumholz,,"""AbbVie Inc (ABBV.N) forecast its flagship drug Humira to bring $21 billion in sales by 2020‚Äù; should be able to allocate adequate resources to investigate deaths? There should be transparency in post-market surveillance. And investment.  https://t.co/huDitJZqX8  https://t.co/evR3WGzLQh",en,[],['https://www.fiercepharma.com/pharma/abbvie-slammed-by-fda-for-improper-handling-humira-death-complaints-report?mkt_tok=eyJpIjoiWVRobE0ySXlNR0l6WmpWbSIsInQiOiJwUE9pSVwvcm02VjNDZ0NSTVE2TWxHSVdXbGNXTnJ6Qk42VTVZOVwvaG03TVErdndzZGxDQVczM0RPTFBzR3JPV3NXTkJlQVwvZFVHNHd2K1IxYUo5Rlo0c0pocGZWRkVMb0l5M1FnMldXa0JsWEppVENxVU0xdW5DZ01sZmZXb1greSJ9&mrkid=1011536'],['https://pbs.twimg.com/media/DfbwwScUYAAA8du.jpg'],0,4,6,[],[],https://twitter.com/hmkyale/status/1006256283127726080,False,,1,https://pbs.twimg.com/media/DfbwwScUYAAA8du.jpg,,,,,,,[],,,,
996510562887532544,996510562887532544,2018-05-16 03:30:07 IST,2018-05-16,03:30:07,+0530,531892451,abbvie,AbbVie,,Listen in live tomorrow @ 6:20 pm CT to hear $ABBV CEO Richard Gonzalez present at the 2018 Bank of America Merrill Lynch Health Care Conf:   https://t.co/nH6hcIhztl,en,[],['http://bit.ly/2rJwRh8'],[],0,1,11,[],['abbv'],https://twitter.com/abbvie/status/996510562887532544,False,,0,,,,,,,,[],,,,
989659153164636161,989659153164636161,2018-04-27 05:45:03 IST,2018-04-27,05:45:03,+0530,25998862,drugchannels,Adam J. Fein,,"Per @abbvie $ABBV CEO Rick Gonzalez, #copay #accumulators ""4% or so of the #HUMIRA patient volume"" - not ""a major threat"" but ""extremely bad #healthcare policy"" - lots of add'l discussion on 2018:Q1 earnings call - worth reading transcript  https://t.co/rCFSA6GpgT",en,"[{'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",['https://drugch.nl/2r2XyfJ'],[],0,1,4,"['copay', 'accumulators', 'humira', 'healthcare']",['abbv'],https://twitter.com/DrugChannels/status/989659153164636161,False,,0,,,,,,,,[],,,,
989549810121347073,989549810121347073,2018-04-26 22:30:34 IST,2018-04-26,22:30:34,+0530,531892451,abbvie,AbbVie,,"ICYMI: Earlier today, we reported Q1 2018 financial performance. Learn more here:  https://t.co/vXqzvufDeo $ABBV  https://t.co/9czIFADvSn",en,[],['http://bit.ly/2vKdzg6'],['https://pbs.twimg.com/media/DbuWTqpXUAY83S-.jpg'],0,6,22,[],['abbv'],https://twitter.com/abbvie/status/989549810121347073,False,,1,https://pbs.twimg.com/media/DbuWTqpXUAY83S-.jpg,,,,,,,[],,,,
989493069266505729,989493069266505729,2018-04-26 18:45:06 IST,2018-04-26,18:45:06,+0530,531892451,abbvie,AbbVie,,We continue to make investments in our science to support all stages of our pipeline. $ABBV  https://t.co/Re3VwsCCTv,en,[],[],['https://pbs.twimg.com/media/Dbtis56W0AI2jy_.jpg'],0,7,14,[],['abbv'],https://twitter.com/abbvie/status/989493069266505729,False,,1,https://pbs.twimg.com/media/Dbtis56W0AI2jy_.jpg,,,,,,,[],,,,
989490552524693504,989490552524693504,2018-04-26 18:35:06 IST,2018-04-26,18:35:06,+0530,531892451,abbvie,AbbVie,,"In Q1 2018, we achieved double-digit growth. $ABBV  https://t.co/sP7BaGB8Sc",en,[],[],['https://pbs.twimg.com/media/DbtgaZvXkAA59fz.jpg'],0,2,20,[],['abbv'],https://twitter.com/abbvie/status/989490552524693504,False,,1,https://pbs.twimg.com/media/DbtgaZvXkAA59fz.jpg,,,,,,,[],,,,
989474655458050049,989474655458050049,2018-04-26 17:31:56 IST,2018-04-26,17:31:56,+0530,913260122004086784,kessanman,Á±≥ÂõΩÊ†™ Ê±∫ÁÆó„Éû„É≥,,„Ç¢„ÉÉ„É¥„Ç£Ê±∫ÁÆó AbbVie (NYSE:ABBV) Q1 EPS $1.87 ‰∫àÊÉ≥ +$0.08 Â£≤‰∏ä $7.93B (+21.3% Y/Y) ‰∫àÊÉ≥ +$330M  „Éí„É•„Éü„É©„ÅßÁü•„Çâ„Çå„Çã„Éê„Ç§„Ç™ÂåªËñ¨ÂìÅ‰ºÅÊ•≠„ÄÇ„Ç¨„Ç§„ÉÄ„É≥„ÇπÂºï„Åç‰∏ä„Åí„ÄÇ  https://t.co/ueK7KGZJ2P  https://t.co/rYVs8TXINd,ja,[],['http://investors.abbvie.com/phoenix.zhtml?c=251551&p=irol-newsArticle&ID=2344878'],['https://pbs.twimg.com/media/DbtQ1wcUwAAKj5g.jpg'],0,5,10,[],[],https://twitter.com/KessanMan/status/989474655458050049,False,,1,https://pbs.twimg.com/media/DbtQ1wcUwAAKj5g.jpg,,,,,,,[],,,,
989471144981000192,989471144981000192,2018-04-26 17:17:59 IST,2018-04-26,17:17:59,+0530,59393368,livesquawk,LiveSquawk,,$ABBV AbbVie Q1 18 Earnings Results: - Adj EPS: $1.87 (Estimate $1.79) - Revenue: $7.93B (Estimate $7.60B),en,[],[],[],0,6,5,[],['abbv'],https://twitter.com/LiveSquawk/status/989471144981000192,False,,0,,,,,,,,[],,,,
982102851840176128,982102851840176128,2018-04-06 09:19:01 IST,2018-04-06,09:19:01,+0530,3460109487,endpts,Endpoints News,,$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023  https://t.co/1hLcvNHUf5 $ABBV,en,[],['https://endpts.com/21b-or-bust-abbvie-ensures-its-blockbuster-us-marathon-on-humira-will-run-into-2023/'],[],0,2,6,[],['abbv'],https://twitter.com/endpts/status/982102851840176128,False,,0,,,,,,,,[],,,,
982011021136101376,982011021136101376,2018-04-06 03:14:06 IST,2018-04-06,03:14:06,+0530,102754598,johncendpts,John Carroll,,#2 $21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023 $ABBV  https://t.co/zKi23LfrQW,en,[],['https://endpts.com/21b-or-bust-abbvie-ensures-its-blockbuster-us-marathon-on-humira-will-run-into-2023/'],[],0,2,5,[],['abbv'],https://twitter.com/JohnCendpts/status/982011021136101376,False,,0,,,,,,,,[],,,,
981882674603229185,981882674603229185,2018-04-05 18:44:06 IST,2018-04-05,18:44:06,+0530,102754598,johncendpts,John Carroll,,$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023 $ABBV   https://t.co/zKi23LfrQW,en,[],['https://endpts.com/21b-or-bust-abbvie-ensures-its-blockbuster-us-marathon-on-humira-will-run-into-2023/'],[],0,8,16,[],['abbv'],https://twitter.com/JohnCendpts/status/981882674603229185,False,,0,,,,,,,,[],,,,
981870824805359617,981870824805359617,2018-04-05 17:57:01 IST,2018-04-05,17:57:01,+0530,6810242,bydavidcrow,David Crow,,"Beginning of the end: AbbVie resolves Humira patent dispute with  Samsung Bioepis, paving way for launch of first copycat biosimilar versions of world‚Äôs best-selling drug $ABBV  https://t.co/tLklPHaGHC",en,[],['https://news.abbvie.com/article_display.cfm?article_id=11627#.WsYVhriaixY.twitter'],[],1,10,13,[],['abbv'],https://twitter.com/bydavidcrow/status/981870824805359617,False,,0,,,,,,,,[],,,,
981867636794458112,981867636794458112,2018-04-05 17:44:21 IST,2018-04-05,17:44:21,+0530,632341632,andybiotech,Andy Biotech,,"$ABBV $BIIB Settlement on Humira #Biosimilar in Europe --&gt; Biogen expects to launch IMRALDI in Europe on October 16, 2018  AbbVie will grant patent licenses on a country-by-country basis, and receives royalty payments  CC @biosimilarz @ZacharyBrennan",en,"[{'screen_name': 'biosimilarz', 'name': 'biosimilarz', 'id': '239982538'}, {'screen_name': 'zacharybrennan', 'name': 'zach brennan', 'id': '605657704'}]",[],[],2,10,14,['biosimilar'],"['abbv', 'biib']",https://twitter.com/AndyBiotech/status/981867636794458112,False,,0,,,,,,,,[],,,,
976824801674309632,976824801674309632,2018-03-22 19:45:55 IST,2018-03-22,19:45:55,+0530,1544270486,ibd_ecarson,Ed Carson,,"Abbvie, which was setting up, plunges 11% on cancer drug news. Tencent falls 8% after Wednesday's 3% tumble.   Backs up this story on why investors should resist the temptation to buy a stock just below a buy point. $ABBV $TCEHY $FB $GOOGL $ORCL $HTHT   https://t.co/Vhy1RX1FVB",en,[],['https://twitter.com/IBDinvestors/status/976601896352759808'],[],1,3,5,[],"['abbv', 'tcehy', 'fb', 'googl', 'orcl', 'htht']",https://twitter.com/IBD_ECarson/status/976824801674309632,False,https://twitter.com/IBDinvestors/status/976601896352759808,0,,,,,,,,[],,,,
976804995445161989,976804995445161989,2018-03-22 18:27:13 IST,2018-03-22,18:27:13,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$abbv ""negative TRINITY result due to safety issues would eliminate $1.5bn from peak consensus revenue, remove upside opportunities and catalysts f orlabel expansions, and would lower the #credibility of AbbVie‚Äôs business development team""  leerink recently",en,[],[],[],1,2,5,['credibility'],['abbv'],https://twitter.com/_B_I_O_T_E_C_H_/status/976804995445161989,False,,0,,,,,,,,[],,,,
971347616796733440,971345406641758208,2018-03-07 17:01:33 IST,2018-03-07,17:01:33,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@tgtxdough What was the combined revenues for $ABBV &amp; $BIIB in #MS? Surely $TGTX will be an $ABBV target now. It threatens to cannibalize #ibrutinib sales and they have a promising #MS drug! @abbvie what do you think?,en,"[{'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",[],[],0,0,5,"['ms', 'ibrutinib', 'ms']","['abbv', 'biib', 'tgtx', 'abbv']",https://twitter.com/Biotech2050/status/971347616796733440,False,,0,,,,,,,,[],,,,
966409077944475648,966409077944475648,2018-02-22 01:57:33 IST,2018-02-22,01:57:33,+0530,102754598,johncendpts,John Carroll,,#3 AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII $ABBV  https://t.co/aWkeDeDpD7,en,[],['https://endpts.com/abbvie-rolls-up-another-big-win-for-elagolix-as-the-prospective-blockbuster-sweeps-endpoints-in-latest-phiii/'],[],0,5,10,[],['abbv'],https://twitter.com/JohnCendpts/status/966409077944475648,False,,0,,,,,,,,[],,,,
965925311778099200,965925311778099200,2018-02-20 17:55:15 IST,2018-02-20,17:55:15,+0530,102754598,johncendpts,John Carroll,,"AbbVie steers past the wreckage, reserves $224M to kick off a new approach with Voyager to fight Alzheimer‚Äôs $ABBV $VYGR  https://t.co/geNm2I67hx",en,[],['https://endpts.com/abbvie-steers-past-the-wreckage-reserves-224m-to-kick-off-a-new-approach-with-voyager-to-fight-alzheimers/'],[],1,8,17,[],"['abbv', 'vygr']",https://twitter.com/JohnCendpts/status/965925311778099200,False,,0,,,,,,,,[],,,,
964656216243806210,964656216243806210,2018-02-17 05:52:19 IST,2018-02-17,05:52:19,+0530,174087270,freetonsha,Á©ÇÈ´ò ÂîØÂ∏åÔΩúYuiki Hotaka,,„Ç¢„ÉÉ„É¥„Ç£„ÄÇÂ∞ëÈ°çÊäïË≥á„Å™„Åå„ÇâÂ¨â„Åó„ÅÑ„Éã„É•„Éº„Çπ„Åß„Åô„ÄÇ  „ÄêABBV„ÄëAbbVie„Åå35.2%„ÅÆÂ§ßÂπÖÂ¢óÈÖçÔºÅYoC„Åå‰∏ÄÊ∞ó„Å´6.4%„Å´ÔºÅ  https://t.co/bXSIgP44iH,ja,[],['https://freetonsha.com/2018/02/17/abbvie-huge-zouhai/'],[],1,1,26,[],[],https://twitter.com/FREETONSHA/status/964656216243806210,False,,0,,,,,,,,[],,,,
964619343303553024,964619343303553024,2018-02-17 03:25:47 IST,2018-02-17,03:25:47,+0530,726020443455414272,8do9do,„ÅØ„Å°„Å©„ÅÜ@‰∏ñÁïå‰∏Ä„ÇÑ„Åï„Åó„ÅÑ Á±≥ÂõΩÊ†™„ÅÆÊïôÁßëÊõ∏ 1Âπ¥Áîü,,AbbVie declares $0.96 dividend $ABBV  https://t.co/iZK9MIW8XE,ca,[],['http://www.seekingalpha.com/news/3331566'],[],0,0,5,[],['abbv'],https://twitter.com/8do9do/status/964619343303553024,False,,0,,,,,,,,[],,,,
964437462893453312,964437462893453312,2018-02-16 15:23:04 IST,2018-02-16,15:23:04,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,#genome #editing to #cure #HIV #infection (Using $SGMO Zinc finger)  @GileadSciences @abbvie @pfizer @bmsnews @Celgene @NovartisScience @VasNarasimhan @Amgen @biogen @sanofi @Roche  $GILD $ABBV $PFE $BMY $CELG $NVS $AMGN $BIIB $SNY $RHHBY   https://t.co/irVjPxJyJJ,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'vasnarasimhan', 'name': 'vas narasimhan', 'id': '723488741348782080'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}]",['https://www.youtube.com/watch?v=WPp-ip0Nwyk'],[],1,4,7,"['genome', 'editing', 'cure', 'hiv', 'infection']","['sgmo', 'gild', 'abbv', 'pfe', 'bmy', 'celg', 'nvs', 'amgn', 'biib', 'sny', 'rhhby']",https://twitter.com/Biotech2050/status/964437462893453312,False,,0,,,,,,,,[],,,,
964294543939112960,964294543939112960,2018-02-16 05:55:09 IST,2018-02-16,05:55:09,+0530,15568127,themotleyfool,The Motley Fool,,"From where @keithspeights sits, the opportunities for long-term growth out of AbbVie, NVIDIA and Disney look compelling. $ABBV $NVDA $DIS  https://t.co/xbYd0uFyj7",en,"[{'screen_name': 'keithspeights', 'name': 'keith speights', 'id': '27976629'}]",['https://www.fool.com/investing/2018/02/14/3-top-stocks-you-can-buy-and-hold-for-the-next-dec.aspx'],[],0,6,32,[],"['abbv', 'nvda', 'dis']",https://twitter.com/themotleyfool/status/964294543939112960,False,,0,,,,,,,,[],,,,
964245566464151552,964245566464151552,2018-02-16 02:40:32 IST,2018-02-16,02:40:32,+0530,531892451,abbvie,AbbVie,,Today we announced an increase to our quarterly dividend &amp; a new stock repurchase program. Learn more here:  https://t.co/6sUlQXBK3i $ABBV  https://t.co/ZlTtmwkpOI,en,[],['http://bit.ly/2o79sDG'],['https://pbs.twimg.com/media/DWGwO0xVAAA5yeT.jpg'],0,6,18,[],['abbv'],https://twitter.com/abbvie/status/964245566464151552,False,,1,https://pbs.twimg.com/media/DWGwO0xVAAA5yeT.jpg,,,,,,,[],,,,
964209874170195968,964209874170195968,2018-02-16 00:18:42 IST,2018-02-16,00:18:42,+0530,41516710,eddyelfenbein,Eddy Elfenbein,,"AbbVie raises dividend by 35%, new $10 billion buyback. $ABBV",en,[],[],[],6,0,12,[],['abbv'],https://twitter.com/EddyElfenbein/status/964209874170195968,False,,0,,,,,,,,[],,,,
964209012794421249,964209012794421249,2018-02-16 00:15:17 IST,2018-02-16,00:15:17,+0530,18589072,dividendgrowth,Dividend Growth Investor,,"AbbVie $ABBV just announced a 35% increase in its quarterly cash dividend to $0.96 per share. In addition, the board has authorized a new $10B stock repurchase program. The dividend is up 140% since it split from Abbott in 2013...",en,[],[],[],3,4,20,[],['abbv'],https://twitter.com/DividendGrowth/status/964209012794421249,False,,0,,,,,,,,[],,,,
961233180119437313,961233180119437313,2018-02-07 19:10:23 IST,2018-02-07,19:10:23,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear $GILD $PFE $CELG $ABBV $BIIB $NVS $AMGN $RHHBY Successful #geneediting requires that there are no significant adverse events &amp; these: 1. Precision  2. Specificity 3. Efficiency  Only $SGMO can help you achieve this @GileadSciences  @Celgene @pfizer @Roche @abbvie @Amgen  https://t.co/jdtY5ZIDNM,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}]",[],['https://pbs.twimg.com/media/DVb8e4rX0AAEwZY.jpg'],1,6,12,['geneediting'],"['gild', 'pfe', 'celg', 'abbv', 'biib', 'nvs', 'amgn', 'rhhby', 'sgmo']",https://twitter.com/Biotech2050/status/961233180119437313,False,,1,https://pbs.twimg.com/media/DVb8e4rX0AAEwZY.jpg,,,,,,,[],,,,
959397576834535428,959397576834535428,2018-02-02 17:36:21 IST,2018-02-02,17:36:21,+0530,6810242,bydavidcrow,David Crow,,"AbbVie's tax rate in 2018 is 9%; Amgen 14-15%; Pfizer 17%; Merck 19-20%. How's that ""level playing field"" going? $ABBV, $AMGN, $PFE, $MRK",en,[],[],[],1,9,25,[],"['abbv', 'amgn', 'pfe', 'mrk']",https://twitter.com/bydavidcrow/status/959397576834535428,False,,0,,,,,,,,[],,,,
957528239806844934,957528239806844934,2018-01-28 13:48:17 IST,2018-01-28,13:48:17,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,KOL Kathryn Kolibaba on ‚ÄúCurrent treatment and future plans in the treatment of front line &amp; RR #CLL ‚Äú Listen to what she says (links below)  $TGTX is @abbvie $ABBV ‚Äòs upcoming competitor as it will dominate the market on approval.  https://t.co/a0FC8JORKx   https://t.co/teJ7yKjMtF,en,"[{'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]","['http://files.shareholder.com/downloads/MHA/1998441175x0x966348/611A2B92-B1DC-44FA-A12F-F1F0FBC4BB41/ASH_2017_Investor_Deck_Final.pdf', 'http://www.investorcalendar.com/event/22901']",[],0,6,14,['cll'],"['tgtx', 'abbv']",https://twitter.com/Biotech2050/status/957528239806844934,False,,0,,,,,,,,[],,,,
957111024225832960,957024896743178240,2018-01-27 10:10:25 IST,2018-01-27,10:10:25,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@tgtxdough Next move by $ABBV @abbvie could be: 1. $TGTX to contain competition  2. $SGMO to wipe out $GILD in #HIV and to be leaders in #Alzheimers using #TAU potential. ABBV might also diversify into #RareDiseases,en,"[{'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",[],[],2,2,9,"['hiv', 'alzheimers', 'tau', 'rarediseases']","['abbv', 'tgtx', 'sgmo', 'gild']",https://twitter.com/Biotech2050/status/957111024225832960,False,,0,,,,,,,,[],,,,
956989952482570241,956989952482570241,2018-01-27 02:09:19 IST,2018-01-27,02:09:19,+0530,6810242,bydavidcrow,David Crow,,"Drugmaker AbbVie makes ‚Äòjaw dropping‚Äô forecast on tax boon, becoming one of biggest beneficiaries of Trump's reforms. Will pay 9pc tax this year. $ABBV  https://t.co/8NtBYFTYvd",en,[],['https://www.ft.com/content/3050ea52-02ba-11e8-9650-9c0ad2d7c5b5'],[],1,9,14,[],['abbv'],https://twitter.com/bydavidcrow/status/956989952482570241,False,,0,,,,,,,,[],,,,
956987896883396608,956951038686318592,2018-01-27 02:01:09 IST,2018-01-27,02:01:09,+0530,463177571,mchilberg,Marty Chilberg,,@Biotech2050 @abbvie @GileadSciences @_B_I_O_T_E_C_H_ $ABBV is my sleeper pick for an $SGMO collaboration and eventual acquisition.  Not the most probable but the overlap of their therapeutic int and Sangamo research areas is interesting  https://t.co/Qhejv6bmrR,en,[],['http://bridgeandtunnelinvestor.com/thread/162/abbv-abbvie'],[],0,4,14,[],"['abbv', 'sgmo']",https://twitter.com/mchilberg/status/956987896883396608,False,,0,,,,,,,,"[{'screen_name': 'Biotech2050', 'name': 'Biotech2050 üíé‚úã', 'id': '2494896473'}, {'screen_name': 'abbvie', 'name': 'AbbVie', 'id': '531892451'}, {'screen_name': 'GileadSciences', 'name': 'Gilead Sciences', 'id': '309728693'}, {'screen_name': '_B_I_O_T_E_C_H_', 'name': 'üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑', 'id': '4859660471'}]",,,,
956951443264737281,956951443264737281,2018-01-26 23:36:18 IST,2018-01-26,23:36:18,+0530,14886375,stocktwits,Stocktwits,,Two stocks are making massive moves today. But no one is talking about them. First up is AbbVie. It's up 11% right now and hitting ALL-TIME HIGHS.  $ABBV -&gt;  https://t.co/jqAlUhtvRN  https://t.co/itBx9rwzZ4,en,[],['https://stocktwits.com/symbol/ABBV'],['https://pbs.twimg.com/media/DUfGPYbUQAAqzvi.jpg'],3,6,17,[],['abbv'],https://twitter.com/Stocktwits/status/956951443264737281,False,,1,https://pbs.twimg.com/media/DUfGPYbUQAAqzvi.jpg,,,,,,,[],,,,
956914669016379395,956910232608780289,2018-01-26 21:10:10 IST,2018-01-26,21:10:10,+0530,351124316,brandonvanzee,ùêÅùê´ùêöùêßùêùùê®ùêß ùêïùêöùêß ùêôùêûùêû,,"@davidsettle42 The fun part of this one is that $ABBV was one of the rare stocks that we owned in BOTH my Trading Rooms... Income Investing and Top-Down Trend Trading. Very good chance that if a student had attended my classes in the last 5 years, they are very familiar with AbbVie.",en,[],[],[],1,2,21,[],['abbv'],https://twitter.com/BrandonVanZee/status/956914669016379395,False,,0,,,,,,,,"[{'screen_name': 'davidsettle42', 'name': 'David Settle, CMT', 'id': '210153565'}]",,,,
956907105751052289,956907105751052289,2018-01-26 20:40:07 IST,2018-01-26,20:40:07,+0530,531892451,abbvie,AbbVie,,"In our first 5 years, we have delivered on our commitment to bring promising treatments to patients. Learn more about our impact here:  https://t.co/gpXVDLPOmv  $ABBV  https://t.co/Y6mqMAG5A4",en,[],['http://bit.ly/2DLq7qz'],['https://pbs.twimg.com/media/DUed8MBVMAA3gM_.jpg'],1,15,40,[],['abbv'],https://twitter.com/abbvie/status/956907105751052289,False,,1,https://pbs.twimg.com/media/DUed8MBVMAA3gM_.jpg,,,,,,,[],,,,
956873087420690433,956873087420690433,2018-01-26 18:24:56 IST,2018-01-26,18:24:56,+0530,475524030,wallstjesus,JE$US,,"$ABBV AbbVie beats by $0.04, beats on revenue  https://t.co/FIU1POKY3O $ABBV  https://t.co/fzcGC8wiOJ",en,[],['https://seekingalpha.com/news/3325657?source=ansh'],['https://pbs.twimg.com/media/DUd-_2DUMAAAehU.jpg'],0,7,6,[],"['abbv', 'abbv']",https://twitter.com/WallStJesus/status/956873087420690433,False,,1,https://pbs.twimg.com/media/DUd-_2DUMAAAehU.jpg,,,,,,,[],,,,
956872502663372800,956872502663372800,2018-01-26 18:22:37 IST,2018-01-26,18:22:37,+0530,531892451,abbvie,AbbVie,,Our FY2017 and Q4 results have been announced. Learn more about our performance:  https://t.co/kjHY38YA1G $ABBV  https://t.co/scHG5OQmHD,en,[],['http://bit.ly/2DI09or'],['https://pbs.twimg.com/media/DUd-eBXU0AAP5sV.jpg'],0,3,9,[],['abbv'],https://twitter.com/abbvie/status/956872502663372800,False,,1,https://pbs.twimg.com/media/DUd-eBXU0AAP5sV.jpg,,,,,,,[],,,,
956702003148795904,956702003148795904,2018-01-26 07:05:06 IST,2018-01-26,07:05:06,+0530,15568127,themotleyfool,The Motley Fool,,"In your quest to snag stocks that are both growth and income plays, @KeithSpeights suggests you check out AbbVie, Brookfield Infrastructure Partners &amp; Iron Mountain. $ABBV, $BIP $IRM  https://t.co/r6O5Q4sLU2",en,"[{'screen_name': 'keithspeights', 'name': 'keith speights', 'id': '27976629'}]",['https://www.fool.com/investing/2018/01/24/3-stocks-to-help-you-build-retirement-wealth.aspx'],[],0,3,19,[],"['abbv', 'bip', 'irm']",https://twitter.com/themotleyfool/status/956702003148795904,False,,0,,,,,,,,[],,,,
955893690077253633,955893690077253633,2018-01-24 01:33:10 IST,2018-01-24,01:33:10,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @pfizer @GileadSciences @Celgene @Shireplc @NovartisScience @sanofi @Amgen @roche @abbvie Please be aware of the patent granted today to $SGMO before you enter into an agreement with any #CRISPR Company $PFE $GILD $CELG $SHPG $NVS $SNY $RHBBY $ABBV    https://t.co/H1Vwva4Wd2,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",['https://twitter.com/_B_I_O_T_E_C_H_/status/955871845697380352'],[],0,3,10,['crispr'],"['sgmo', 'pfe', 'gild', 'celg', 'shpg', 'nvs', 'sny', 'rhbby', 'abbv']",https://twitter.com/Biotech2050/status/955893690077253633,False,https://twitter.com/_B_I_O_T_E_C_H_/status/955871845697380352,0,,,,,,,,[],,,,
943473267041587203,943473267041587203,2017-12-20 18:58:50 IST,2017-12-20,18:58:50,+0530,18294197,fiercebiotech,FierceBiotech,,"One patient, which AbbVie says had ‚Äúpre-existing cardiovascular risk factors,‚Äù died of a hemorrhagic stroke caused by a ruptured aneurysm, while on the lower dose form of its med:  https://t.co/nVZ9eYRVrd $ABBV",en,[],['http://ow.ly/TTz330hltBa'],[],2,3,4,[],['abbv'],https://twitter.com/FierceBiotech/status/943473267041587203,False,,0,,,,,,,,[],,,,
935636058468966400,935636058468966400,2017-11-29 03:56:34 IST,2017-11-29,03:56:34,+0530,1069486704,wolfmetric,Wolfmetric,,AbbVie $ABBV shares are setting up after a strong run ahead of the ASH conference - Trade of the Week    https://t.co/tDFxASXooi,en,[],['http://www.optionshawk.com/trade-of-the-week/'],[],0,5,12,[],['abbv'],https://twitter.com/Wolfmetric/status/935636058468966400,False,,0,,,,,,,,[],,,,
923904689191751681,923904689191751681,2017-10-27 19:00:17 IST,2017-10-27,19:00:17,+0530,531892451,abbvie,AbbVie,,We are positioned to continue to meet the needs of patients with our innovative medicines. Learn more:  https://t.co/09yDEpcuzS $ABBV  https://t.co/1PtAlF7ODM,en,[],['http://bit.ly/2zSFXL0'],['https://pbs.twimg.com/media/DNJeasQXkAAdORi.jpg'],0,8,31,[],['abbv'],https://twitter.com/abbvie/status/923904689191751681,False,,1,https://pbs.twimg.com/media/DNJeasQXkAAdORi.jpg,,,,,,,[],,,,
923877270640648192,923877270640648192,2017-10-27 17:11:20 IST,2017-10-27,17:11:20,+0530,2723696479,dividendhike,dividend hike,,AbbVie hikes dividend by 10.9% to $0.71 quarterly. $ABBV @dividendaristo,en,"[{'screen_name': 'dividendaristo', 'name': 'dividend aristocrats', 'id': '2147886180'}]",[],[],1,7,25,[],['abbv'],https://twitter.com/dividendhike/status/923877270640648192,False,,0,,,,,,,,[],,,,
923877104067989504,923877104067989504,2017-10-27 17:10:41 IST,2017-10-27,17:10:41,+0530,531892451,abbvie,AbbVie,,$ABBV reports 11% increase in our quarterly dividend this morning. Learn more:  https://t.co/tAXgmZleHM  https://t.co/aw9aBqtyqd,en,[],['http://bit.ly/2ll3TU7'],['https://pbs.twimg.com/media/DNJFVDmX4AAMA-t.jpg'],0,5,23,[],['abbv'],https://twitter.com/abbvie/status/923877104067989504,False,,1,https://pbs.twimg.com/media/DNJFVDmX4AAMA-t.jpg,,,,,,,[],,,,
922779800422543360,922779800422543360,2017-10-24 16:30:23 IST,2017-10-24,16:30:23,+0530,102754598,johncendpts,John Carroll,,AbbVie antes up $225M in cash to buy into the neurodegeneration platform at Alector $ABBV  https://t.co/kvVKU03Rhu,en,[],['https://endpts.com/abbvie-antes-up-225m-in-cash-to-buy-into-the-neurodegeneration-platform-at-alector/'],[],0,8,18,[],['abbv'],https://twitter.com/JohnCendpts/status/922779800422543360,False,,0,,,,,,,,[],,,,
913423592104382464,913423592104382464,2017-09-28 20:52:09 IST,2017-09-28,20:52:09,+0530,2527835190,bobjherman,Bob Herman,,Wall St. is giddy AbbVie locked in Humira monopoly pricing until 2023. $ABBV up almost 6%.  https://t.co/qSWDnJK88E,en,[],['https://www.axios.com/drug-company-settlement-delays-humira-competition-2490536187.html'],[],1,10,4,[],['abbv'],https://twitter.com/bobjherman/status/913423592104382464,False,,0,,,,,,,,[],,,,
913397038175412224,913397038175412224,2017-09-28 19:06:38 IST,2017-09-28,19:06:38,+0530,102754598,johncendpts,John Carroll,,AbbVie wins a 5-year free pass on mega-blockbuster Humira in biosim settlement with rival Amgen $AMGN $ABBV +4%  https://t.co/yb4l5653ab,en,[],['https://endpts.com/abbvie-wins-a-5-year-free-pass-on-mega-blockbuster-humira-in-biosim-settlement-with-rival-amgen/'],[],2,10,13,[],"['amgn', 'abbv']",https://twitter.com/JohnCendpts/status/913397038175412224,False,,0,,,,,,,,[],,,,
910096182252326913,910096182252326913,2017-09-19 16:30:13 IST,2017-09-19,16:30:13,+0530,18294197,fiercebiotech,FierceBiotech,,"Atlas neurological upstart Disarm gains $30M, AbbVie backing:  https://t.co/HPvaRAtCZa $ABBV",en,[],['http://ow.ly/KyB030fgmZi'],[],0,2,12,[],['abbv'],https://twitter.com/FierceBiotech/status/910096182252326913,False,,0,,,,,,,,[],,,,
908056179447877632,908056179447877632,2017-09-14 01:23:58 IST,2017-09-14,01:23:58,+0530,61342056,optionshawk,Joe Kunkle,,The only more impressive streak than the Indians is AbbVie $ABBV,en,[],[],[],2,2,17,[],['abbv'],https://twitter.com/OptionsHawk/status/908056179447877632,False,,0,,,,,,,,[],,,,
906177853011742720,906177853011742720,2017-09-08 21:00:10 IST,2017-09-08,21:00:10,+0530,531892451,abbvie,AbbVie,,$ABBV declares quarterly #dividend of $0.64 per share.  Learn more:  https://t.co/z5qqJ2ox7m  https://t.co/x6kB7wC9Z3,en,[],['http://bit.ly/2xbybx5'],['https://pbs.twimg.com/media/DJNj9DsW0AAUrg3.jpg'],0,2,10,['dividend'],['abbv'],https://twitter.com/abbvie/status/906177853011742720,False,,1,https://pbs.twimg.com/media/DJNj9DsW0AAUrg3.jpg,,,,,,,[],,,,
905370223267733505,905370223267733505,2017-09-06 15:30:56 IST,2017-09-06,15:30:56,+0530,102754598,johncendpts,John Carroll,,Verastem‚Äôs low-stakes comeback gamble on an AbbVie/Infinity castoff pays off with positive data $VSTM $INFI $ABBV  https://t.co/09JlrpERyt,en,[],['https://endpts.com/verastems-low-stakes-comeback-gamble-on-an-abbvieinfinity-castoff-pays-off-with-positive-data/'],[],1,4,6,[],"['vstm', 'infi', 'abbv']",https://twitter.com/JohnCendpts/status/905370223267733505,False,,0,,,,,,,,[],,,,
893427185947738112,893427185947738112,2017-08-04 16:33:34 IST,2017-08-04,16:33:34,+0530,102754598,johncendpts,John Carroll,,"Look out Gilead, AbbVie‚Äôs hep C combo comes with stellar data, 8-week regimen and a killer price $GILD $ABBV $ENTA  https://t.co/3Px16y1kxu",en,[],['https://endpts.com/look-out-gilead-abbvies-hep-c-combo-comes-with-stellar-data-8-week-regimen-and-a-killer-price/'],[],0,19,13,[],"['gild', 'abbv', 'enta']",https://twitter.com/JohnCendpts/status/893427185947738112,False,,0,,,,,,,,[],,,,
892811491174428673,892811491174428673,2017-08-02 23:47:01 IST,2017-08-02,23:47:01,+0530,454898193,plmccarthymd,Philip McCarthy,,FDA OKs AbbVie's Imbruvica for chronic graft-vs-host disease  https://t.co/tYbXEyVxZ9 $ABBV  https://t.co/vBNKgLvZ6J,en,[],"['https://seekingalpha.com/news/3284507-fda-oks-abbvies-imbruvica-chronic-graft-vs-host-disease?source=tweet', 'https://seekingalpha.com/news/3284507-fda-oks-abbvies-imbruvica-chronic-graft-vs-host-disease']",[],0,7,10,[],['abbv'],https://twitter.com/PLMcCarthyMD/status/892811491174428673,False,,0,,,,,,,,[],,,,
890901431204663297,890901431204663297,2017-07-28 17:17:08 IST,2017-07-28,17:17:08,+0530,531892451,abbvie,AbbVie,,$ABBV Q2 2017 financial results beat expectations. Read more:  https://t.co/8WncOt56AS  https://t.co/RdkEIAjYvR,en,[],['http://bit.ly/2uJ0wY0'],['https://pbs.twimg.com/tweet_video_thumb/DF0eILuXgAAmmwk.jpg'],0,1,6,[],['abbv'],https://twitter.com/abbvie/status/890901431204663297,False,,1,https://pbs.twimg.com/tweet_video_thumb/DF0eILuXgAAmmwk.jpg,,,,,,,[],,,,
877980287128354818,877980287128354818,2017-06-23 01:33:07 IST,2017-06-23,01:33:07,+0530,531892451,abbvie,AbbVie,,$ABBV declares a quarterly #dividend of $0.64 per share:  https://t.co/ycnTgXkdmJ  https://t.co/TufgHS3GHo,en,[],['http://bit.ly/2rHw8uQ'],['https://pbs.twimg.com/media/DC82arSWAAEYK-r.jpg'],0,1,11,['dividend'],['abbv'],https://twitter.com/abbvie/status/877980287128354818,False,,1,https://pbs.twimg.com/media/DC82arSWAAEYK-r.jpg,,,,,,,[],,,,
872514080476626953,872514080476626953,2017-06-07 23:32:21 IST,2017-06-07,23:32:21,+0530,102754598,johncendpts,John Carroll,,AbbVie gets a big boost in the major league rheumatoid arthritis finals with promising PhIII data $ABBV $GILD etc  https://t.co/zEOAi5b8V9,en,[],['https://endpts.com/abbvie-gets-a-big-boost-in-the-major-league-rheumatoid-arthritis-finals-with-promising-phiii-data/'],[],0,6,11,[],"['abbv', 'gild']",https://twitter.com/JohnCendpts/status/872514080476626953,False,,0,,,,,,,,[],,,,
865733858087579648,865733858087579648,2017-05-20 06:30:10 IST,2017-05-20,06:30:10,+0530,102754598,johncendpts,John Carroll,,The PM bureau: AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix $ABBV $NBIX  https://t.co/tETIVVM1hS,en,[],['https://endpts.com/abbvie-preps-an-fda-pitch-of-promising-phiii-data-for-blockbuster-hopeful-elagolix/'],[],0,5,6,[],"['abbv', 'nbix']",https://twitter.com/JohnCendpts/status/865733858087579648,False,,0,,,,,,,,[],,,,
864603277727416321,864603277727416321,2017-05-17 03:37:39 IST,2017-05-17,03:37:39,+0530,31546412,tradehawk,TradeHawk,,$ABBV $CHRS Coherus BioSciences prevails in IPR final decision as AbbVie '135 Humira patent claims are invalidated.  https://t.co/MSHfg1iSsG,en,[],['https://www.scribd.com/document/348562736/Coherus-Biosciences-vs-AbbVie-135-IPR-Final-Written-Decision'],[],1,12,7,[],"['abbv', 'chrs']",https://twitter.com/TradeHawk/status/864603277727416321,False,,0,,,,,,,,[],,,,
857614708236484608,857614708236484608,2017-04-27 20:47:34 IST,2017-04-27,20:47:34,+0530,2301944706,r4inb0w_,R4inb0w,,üîî$ABBV : Genfit Climbs as AbbVie Eyes NASH Market $GNFT #Elafibranor  https://t.co/ywTDnpgGBF,en,[],[],['https://pbs.twimg.com/media/C-bbmZPXoAEaJ-Z.jpg'],0,24,16,['elafibranor'],['gnft'],https://twitter.com/R4inb0w_/status/857614708236484608,False,,1,https://pbs.twimg.com/media/C-bbmZPXoAEaJ-Z.jpg,,,,,,,[],,,,
857560740559015936,857560740559015936,2017-04-27 17:13:07 IST,2017-04-27,17:13:07,+0530,531892451,abbvie,AbbVie,,$ABBV Q1 2017 financial results now available. Read more about the start of 2017:  https://t.co/n10l9sTA9h  https://t.co/DagHdmMaSH,en,[],['http://bit.ly/2p7dL3B'],['https://pbs.twimg.com/media/C-aq8qpWsAABXja.jpg'],0,8,10,[],['abbv'],https://twitter.com/abbvie/status/857560740559015936,False,,1,https://pbs.twimg.com/media/C-aq8qpWsAABXja.jpg,,,,,,,[],,,,
854832709276971009,854832709276971009,2017-04-20 04:32:54 IST,2017-04-20,04:32:54,+0530,102754598,johncendpts,John Carroll,,AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop $ABBV  https://t.co/ZEevMguE2v,en,[],['https://endpts.com/abbvie-grapples-with-another-setback-as-2-phiii-trials-for-its-parp-veliparib-flop/'],[],0,7,5,[],['abbv'],https://twitter.com/JohnCendpts/status/854832709276971009,False,,0,,,,,,,,[],,,,
832526222462709762,832526222462709762,2017-02-17 15:14:53 IST,2017-02-17,15:14:53,+0530,27976629,keithspeights,Keith Speights,,Why I Just Bought AbbVie Stock @themotleyfool #stocks $ABBV  https://t.co/IpJIlFFVgp,en,"[{'screen_name': 'themotleyfool', 'name': 'the motley fool', 'id': '15568127'}]",['https://www.fool.com/investing/2017/02/15/why-i-just-bought-abbvie-stock.aspx'],[],1,2,10,['stocks'],['abbv'],https://twitter.com/keithspeights/status/832526222462709762,False,,0,,,,,,,,[],,,,
826519078915280897,826519078915280897,2017-02-01 01:24:39 IST,2017-02-01,01:24:39,+0530,2829242078,miyatamitsuru,Mm„ÅÆÊÜÇÈ¨±,,WM„ÅÆÊÜÇÈ¨±„ÄÇ„Ç¢„É´„ÉÑ„Éè„Ç§„Éû„ÉºÁóÖ„ÅÆÊ≤ªÁôÇÊ®ôÁöÑ„ÅÆ„Éù„Çπ„ÉàAŒ≤„Å®„Åó„Å¶ÊúâÊúõ„Å™„Çø„Ç¶„Åü„Çì„Å±„ÅèË≥™„Å´ÂØæ„Åô„ÇãÊäó‰ΩìÂåªËñ¨ABBV-8E12„ÅÆ„Éï„Çß„Éº„Ç∫ÔºíÊ≤ªÈ®ì„ÇíÁ±≥AbbvieÁ§æ„ÅåÈñãÂßã„Åó„Åü„ÄÇ  https://t.co/ck2flxTt00,ja,[],['https://news.abbvie.com/alert-topics/neurology/abbvie-initiates-phase-2-clinical-trial-programs-for-abbv-8e12-an-investigational-anti-tau-antibody-in-early-alzheimers-disease-and-progressive-supranuclear-palsy.htm'],[],0,10,20,[],[],https://twitter.com/miyatamitsuru/status/826519078915280897,False,,0,,,,,,,,[],,,,
825329606064377856,825329606064377856,2017-01-28 18:38:06 IST,2017-01-28,18:38:06,+0530,531892451,abbvie,AbbVie,,Bringing innovative new products to patients is why we're here. Take a closer look at our first 4 years:  https://t.co/PzlYb7gOyn $ABBV  https://t.co/FgNKPxtfdQ,en,[],['http://bit.ly/2jm11A0'],['https://pbs.twimg.com/tweet_video_thumb/C3LXSxsVMAAX_3J.jpg'],0,6,17,[],['abbv'],https://twitter.com/abbvie/status/825329606064377856,False,,1,https://pbs.twimg.com/tweet_video_thumb/C3LXSxsVMAAX_3J.jpg,,,,,,,[],,,,
824967713034379265,824967713034379265,2017-01-27 18:40:04 IST,2017-01-27,18:40:04,+0530,531892451,abbvie,AbbVie,,A lot has happened in AbbVie‚Äôs first 4 years. But new products for patients top the list. See $ABBV progress:  https://t.co/PzlYb7gOyn  https://t.co/QewOU0q73d,en,[],['http://bit.ly/2jm11A0'],['https://pbs.twimg.com/tweet_video_thumb/C3LXSxsVMAAX_3J.jpg'],0,9,14,[],['abbv'],https://twitter.com/abbvie/status/824967713034379265,False,,1,https://pbs.twimg.com/tweet_video_thumb/C3LXSxsVMAAX_3J.jpg,,,,,,,[],,,,
819277682500374530,819277682500374530,2017-01-12 01:49:55 IST,2017-01-12,01:49:55,+0530,3043828834,cgrantwsj,Charley Grant,,"Reuters found in April that AbbVie had hiked the price of Humira, world's best selling drug, by 126% since 2011. $ABBV  https://t.co/aXZilEUQf4",en,[],['https://twitter.com/Reuters_Health/status/819271136399785984'],[],0,3,6,[],['abbv'],https://twitter.com/CGrantWSJ/status/819277682500374530,False,https://twitter.com/Reuters_Health/status/819271136399785984,0,,,,,,,,[],,,,
791784097404297216,791784097404297216,2016-10-28 05:00:14 IST,2016-10-28,05:00:14,+0530,531892451,abbvie,AbbVie,,"Join CEO Rick Gonzalez for $ABBV Q3 2016 results at 8am CT, tomorrow, October 28. Learn more:  https://t.co/RxI5t9Olfc  https://t.co/kfgtTzgZYj",en,[],['http://bit.ly/2eWWtOS'],['https://pbs.twimg.com/media/Cvz7cGqXEAEeLQR.jpg'],0,3,9,[],['abbv'],https://twitter.com/abbvie/status/791784097404297216,False,,1,https://pbs.twimg.com/media/Cvz7cGqXEAEeLQR.jpg,,,,,,,[],,,,
768056601848737792,768056601848737792,2016-08-23 17:35:38 IST,2016-08-23,17:35:38,+0530,18294197,fiercebiotech,FierceBiotech,,"Gilead, Galapagos start PhIII of RA drug, 8 months after AbbVie began rival program:  https://t.co/VWOBpOwqdg  $GILD $GLPG $ABBV",en,[],['http://ow.ly/ZOnS303uTVP'],[],0,8,7,[],"['gild', 'glpg', 'abbv']",https://twitter.com/FierceBiotech/status/768056601848737792,False,,0,,,,,,,,[],,,,
762772685877288961,762772685877288961,2016-08-09 03:39:14 IST,2016-08-09,03:39:14,+0530,13171622,pharmalot,pharmalot,,AbbVie and Amgen lock horns in the latest squabble over biosimilars.. a clever legal strategy?  https://t.co/iZrSxjdFi9 #pharma $ABBV $AMGN,en,[],['https://www.statnews.com/pharmalot/2016/08/08/abbvie-amgen-biosimilars-patent/'],[],0,7,6,['pharma'],"['abbv', 'amgn']",https://twitter.com/pharmalot/status/762772685877288961,False,,0,,,,,,,,[],,,,
748970693757394944,748970693757394944,2016-07-02 01:35:03 IST,2016-07-02,01:35:03,+0530,61342056,optionshawk,Joe Kunkle,,"AbbVie $ABBV afternoon buyers of 2,000 November $65 puts $5.60 to $5.70, interesting with late $GILD calls bought too",en,[],[],[],1,10,12,[],"['abbv', 'gild']",https://twitter.com/OptionsHawk/status/748970693757394944,False,,0,,,,,,,,[],,,,
739462251472650245,739462251472650245,2016-06-05 19:51:53 IST,2016-06-05,19:51:53,+0530,18294197,fiercebiotech,FierceBiotech,,AbbVie turns its first card in bold $10B gamble on Rova-T -  https://t.co/7CxUrmtYQM by @JohnCBiotech $ABBV,en,[],['http://www.fiercebiotech.com/abbvie-turns-its-first-card-bold-10b-gamble-rova-t'],[],0,3,6,[],['abbv'],https://twitter.com/FierceBiotech/status/739462251472650245,False,,0,,,,,,,,[],,,,
738777642565050369,738777642565050369,2016-06-03 22:31:30 IST,2016-06-03,22:31:30,+0530,531892451,abbvie,AbbVie,,Recent advances in Alzheimer‚Äôs research are promising. Here‚Äôs why. $ABBV R&amp;D Day  https://t.co/wLFeNyd2DW,en,[],[],['https://pbs.twimg.com/media/CkCqWX_UYAEmXm2.jpg'],0,10,11,[],['abbv'],https://twitter.com/abbvie/status/738777642565050369,False,,1,https://pbs.twimg.com/media/CkCqWX_UYAEmXm2.jpg,,,,,,,[],,,,
738769933195223040,738769933195223040,2016-06-03 22:00:52 IST,2016-06-03,22:00:52,+0530,531892451,abbvie,AbbVie,,Focus of $ABBV Immunology is to continue redefining the standard of care to help patients.  https://t.co/01MPGgQQm3,en,[],[],['https://pbs.twimg.com/tweet_video_thumb/CkCjVo6XEAA8N4n.jpg'],0,10,8,[],['abbv'],https://twitter.com/abbvie/status/738769933195223040,False,,1,https://pbs.twimg.com/tweet_video_thumb/CkCjVo6XEAA8N4n.jpg,,,,,,,[],,,,
738749478576869378,738749478576869378,2016-06-03 20:39:35 IST,2016-06-03,20:39:35,+0530,15563814,loftus,Peter Loftus,,AbbVie CEO Gonzalez sets ambitious goal of 8 non-Humira drugs together generating $25B-$30B annual sales beyond 2020 $ABBV #ASCO16,en,[],[],[],2,10,9,['asco16'],['abbv'],https://twitter.com/Loftus/status/738749478576869378,False,,0,,,,,,,,[],,,,
738743389743681536,738743389743681536,2016-06-03 20:15:23 IST,2016-06-03,20:15:23,+0530,531892451,abbvie,AbbVie,,"Oncology will be a major growth driver for $ABBV over next 10 years &amp; beyond, further diversifying our business.  https://t.co/C6FMTskL2q",en,[],[],['https://pbs.twimg.com/tweet_video_thumb/CkCLMnGUUAE3oCm.jpg'],0,7,12,[],['abbv'],https://twitter.com/abbvie/status/738743389743681536,False,,1,https://pbs.twimg.com/tweet_video_thumb/CkCLMnGUUAE3oCm.jpg,,,,,,,[],,,,
738739712580571136,738739712580571136,2016-06-03 20:00:47 IST,2016-06-03,20:00:47,+0530,531892451,abbvie,AbbVie,,"‚ÄúR&amp;D at AbbVie always starts with an unmet medical need.‚Äù Mike Severino, CSO, shares at $ABBV R&amp;D Day  https://t.co/kZoczDTWo4",en,[],[],['https://pbs.twimg.com/media/CkCH2hHUkAAP5Vg.jpg'],0,15,16,[],['abbv'],https://twitter.com/abbvie/status/738739712580571136,False,,1,https://pbs.twimg.com/media/CkCH2hHUkAAP5Vg.jpg,,,,,,,[],,,,
738737084211601408,738737084211601408,2016-06-03 19:50:20 IST,2016-06-03,19:50:20,+0530,531892451,abbvie,AbbVie,,"$ABBV offers top-tier revenue &amp; EPS growth, significant cash flow &amp; strong return of capital to shareholders.  https://t.co/96eM4o5ZJW",en,[],[],['https://pbs.twimg.com/media/CkCFdhOWYAA2RgI.jpg'],0,8,13,[],['abbv'],https://twitter.com/abbvie/status/738737084211601408,False,,1,https://pbs.twimg.com/media/CkCFdhOWYAA2RgI.jpg,,,,,,,[],,,,
738717158067318784,738717158067318784,2016-06-03 18:31:09 IST,2016-06-03,18:31:09,+0530,531892451,abbvie,AbbVie,,Investors ‚Äì join $ABBV at 9:00 AM CT for a live webcast to hear R&amp;D presentations.  https://t.co/Ss0iNfFKov  https://t.co/Bum5LgwTj1,en,[],['http://ow.ly/FIyI300RUiz'],['https://pbs.twimg.com/media/CkBzVr7XEAEQV8w.jpg'],0,4,6,[],['abbv'],https://twitter.com/abbvie/status/738717158067318784,False,,1,https://pbs.twimg.com/media/CkBzVr7XEAEQV8w.jpg,,,,,,,[],,,,
738709382305853440,738709382305853440,2016-06-03 18:00:15 IST,2016-06-03,18:00:15,+0530,531892451,abbvie,AbbVie,,$ABBV late-stage pipeline has potential to deliver &gt;20 new medicines or indications by 2020  https://t.co/49VLT2Tcwt  https://t.co/8DM2MjmOcW,en,[],['http://ow.ly/QGR0300SJ7q'],['https://pbs.twimg.com/media/CkBsRFnWsAAV8He.jpg'],0,6,12,[],['abbv'],https://twitter.com/abbvie/status/738709382305853440,False,,1,https://pbs.twimg.com/media/CkBsRFnWsAAV8He.jpg,,,,,,,[],,,,
738457052566028289,738457052566028289,2016-06-03 01:17:35 IST,2016-06-03,01:17:35,+0530,531892451,abbvie,AbbVie,,$ABBV oncology development VP envisions new treatment approach for #cancer patients. Learn more at R&amp;D Day.  https://t.co/fMawdE6YdU,en,[],[],[],0,9,16,['cancer'],['abbv'],https://twitter.com/abbvie/status/738457052566028289,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/738456289882349568/pu/img/-AXa_ox3uTOGbZ_6.jpg,,,,,,,[],,,,
738407466501844992,738407466501844992,2016-06-02 22:00:33 IST,2016-06-02,22:00:33,+0530,531892451,abbvie,AbbVie,,We‚Äôre investing in pioneering research for oncology ‚Äì learn more at $ABBV R&amp;D Day:  https://t.co/v3Gd6DFKoB  https://t.co/hOqxojObPW,en,[],['http://ow.ly/pON2300Qq6m'],['https://pbs.twimg.com/media/Cj9ZrUGXIAAEshO.jpg'],0,9,10,[],['abbv'],https://twitter.com/abbvie/status/738407466501844992,False,,1,https://pbs.twimg.com/media/Cj9ZrUGXIAAEshO.jpg,,,,,,,[],,,,
738331988067819520,738331988067819520,2016-06-02 17:00:38 IST,2016-06-02,17:00:38,+0530,531892451,abbvie,AbbVie,,$ABBV presents R&amp;D strategy and outlook to investors tomorrow. Attend webcast:  https://t.co/Wu6kYSAFl6  https://t.co/JXmkkUiYv2,en,[],['http://ow.ly/lWDI300PekQ'],['https://pbs.twimg.com/media/Cj8VBt_VAAAf2iw.jpg'],0,4,5,[],['abbv'],https://twitter.com/abbvie/status/738331988067819520,False,,1,https://pbs.twimg.com/media/Cj8VBt_VAAAf2iw.jpg,,,,,,,[],,,,
738209801537245184,738209801537245184,2016-06-02 08:55:06 IST,2016-06-02,08:55:06,+0530,531892451,abbvie,AbbVie,,Join $ABBV R&amp;D Day June 3 to hear more about our approach in immunology research:  https://t.co/THzRk4fZAI  https://t.co/ZeNJjBnUss,en,[],['http://ow.ly/t4xu300PaMe'],['https://pbs.twimg.com/media/Cj6l5szUkAAwhh7.jpg'],0,8,10,[],['abbv'],https://twitter.com/abbvie/status/738209801537245184,False,,1,https://pbs.twimg.com/media/Cj6l5szUkAAwhh7.jpg,,,,,,,[],,,,
730075097910923265,730075097910923265,2016-05-10 22:10:42 IST,2016-05-10,22:10:42,+0530,15563814,loftus,Peter Loftus,,"An investment banker‚Äôs worst nightmare - M&amp;A without them, like recent AbbVie deal $ABBV  https://t.co/uYaDZIB33T via @WSJ @DanaMattioli",en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}, {'screen_name': 'danamattioli', 'name': 'dana mattioli', 'id': '23892927'}]",['http://on.wsj.com/1WlX5As'],[],0,10,9,[],['abbv'],https://twitter.com/Loftus/status/730075097910923265,False,,0,,,,,,,,[],,,,
725926625427095552,725926625427095552,2016-04-29 11:26:09 IST,2016-04-29,11:26:09,+0530,67066114,dhovekamp42,"`((,(Dieter 'Hovekamp)))",,$GLPG Galapagos and $ABBV AbbVie expand their cystic fibrosis collaboration - milestones now $600M PI&amp;PII  https://t.co/9KOgmCekoT,en,[],['http://www.ariva.de/news/Galapagos-and-AbbVie-expand-their-cystic-fibrosis-collaboration-5732984'],[],0,4,5,[],"['glpg', 'abbv']",https://twitter.com/dhovekamp42/status/725926625427095552,False,,0,,,,,,,,[],,,,
725664227801837568,725664227801837568,2016-04-28 18:03:28 IST,2016-04-28,18:03:28,+0530,18294197,fiercebiotech,FierceBiotech,,"So Sanofi thinks $9.3B is enough for Medivation, then AbbVie pays $9.8B for Stemcentrx, which almost nobody has heard of.. $SNY $ABBV $MDVN",en,[],[],[],1,15,18,[],"['sny', 'abbv', 'mdvn']",https://twitter.com/FierceBiotech/status/725664227801837568,False,,0,,,,,,,,[],,,,
719620076878569472,719620076878569472,2016-04-12 01:46:10 IST,2016-04-12,01:46:10,+0530,15563814,loftus,Peter Loftus,,"Cost of new leukemia drug Venclexta from Roche and AbbVie is about $109,500 per patient for first year of use $ABBV $RHHBY",en,[],[],[],1,15,10,[],"['abbv', 'rhhby']",https://twitter.com/Loftus/status/719620076878569472,False,,0,,,,,,,,[],,,,
719583220996698112,719583220996698112,2016-04-11 23:19:43 IST,2016-04-11,23:19:43,+0530,15563814,loftus,Peter Loftus,,"FDA approves new AbbVie/Roche drug for form of leukemia, Venclexta, first 'BCL-2 inhibitor' $ABBV   https://t.co/iUFHJLwT9E",en,[],['http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm'],[],0,8,11,[],['abbv'],https://twitter.com/Loftus/status/719583220996698112,False,,0,,,,,,,,[],,,,
706924983948173312,706924983948173312,2016-03-08 01:00:24 IST,2016-03-08,01:00:24,+0530,18294275,fiercepharma,FiercePharma,,"J&amp;J, AbbVie's Imbruvica breaks into larger CLL market with first-line FDA nod  https://t.co/RQ4m6T2OXg $JNJ $ABBV #pharma by @CarlyHFierce",en,"[{'screen_name': 'carlyhfierce', 'name': 'carly helfand', 'id': '1379301222'}]",['http://www.fiercepharma.com/story/jj-abbvies-imbruvica-breaks-larger-cll-market-first-line-fda-nod/2016-03-04'],[],0,3,7,['pharma'],"['jnj', 'abbv']",https://twitter.com/FiercePharma/status/706924983948173312,False,,0,,,,,,,,[],,,,
701736287703707649,701736287703707649,2016-02-22 17:22:23 IST,2016-02-22,17:22:23,+0530,818081647,analystwire,SIAnalystWire,,Abbvie $ABBV Named Top Global Pharma Pick at Jefferies  https://t.co/vBrA9CMFGi,en,[],['http://streetinsider.com/r/11343929'],[],0,4,6,[],['abbv'],https://twitter.com/AnalystWire/status/701736287703707649,False,,0,,,,,,,,[],,,,
697397458561867776,697397458561867776,2016-02-10 18:01:25 IST,2016-02-10,18:01:25,+0530,18294197,fiercebiotech,FierceBiotech,,AbbVie taps Synlogic to take a microbiomic approach to IBD.  https://t.co/UgLYhGdAoM by @DamianFierce $ABBV,en,[],['http://www.fiercebiotech.com/story/abbvie-taps-synlogic-take-microbiomic-approach-ibd/2016-02-10'],[],0,9,7,[],['abbv'],https://twitter.com/FierceBiotech/status/697397458561867776,False,,0,,,,,,,,[],,,,
697390513088024576,697390513088024576,2016-02-10 17:33:49 IST,2016-02-10,17:33:49,+0530,50753411,ldtimmerman,Luke Timmerman,,"AbbVie, Maker of World's No. 1 Drug, Bets Synthetic Biology Startup Can Keep it Going. My latest @forbeshealth  https://t.co/IP9jc1gaUZ $ABBV",en,"[{'screen_name': 'forbeshealth', 'name': 'forbes health', 'id': '47443693'}]",['http://www.forbes.com/sites/luketimmerman/2016/02/10/abbvie-maker-of-worlds-no-1-drug-bets-synthetic-biology-startup-can-keep-it-going/#7d2f981772df'],[],0,7,7,[],['abbv'],https://twitter.com/ldtimmerman/status/697390513088024576,False,,0,,,,,,,,[],,,,
693162033961963520,693162033961963520,2016-01-30 01:31:21 IST,2016-01-30,01:31:21,+0530,531892451,abbvie,AbbVie,,"$ABBV 2015 adjusted operating margin of 42.3%, up 6 percentage points over 2014. Read more:  https://t.co/mFW3PZsDSH",en,[],['http://ow.ly/XFYV9'],[],0,2,9,[],['abbv'],https://twitter.com/abbvie/status/693162033961963520,False,,0,,,,,,,,[],,,,
693131810461609984,693131810461609984,2016-01-29 23:31:16 IST,2016-01-29,23:31:16,+0530,531892451,abbvie,AbbVie,,"We anticipate 4 new products or indication approvals in 2016, w/ more #pipeline potential in the next decade. $ABBV  https://t.co/doLIBLwkUH",en,[],[],['https://pbs.twimg.com/media/CZ5_tXjVIAAP6C6.jpg'],0,23,27,['pipeline'],['abbv'],https://twitter.com/abbvie/status/693131810461609984,False,,1,https://pbs.twimg.com/media/CZ5_tXjVIAAP6C6.jpg,,,,,,,[],,,,
687069091711074304,687069091711074304,2016-01-13 06:00:11 IST,2016-01-13,06:00:11,+0530,531892451,abbvie,AbbVie,,Don‚Äôt miss $ABBV CEO Richard Gonzalez live from #JPM16 at 10:30am CT tomorrow.  https://t.co/nPeAVAsGqB,en,[],[],['https://pbs.twimg.com/media/CYj1ssTUoAAj8pr.jpg'],0,11,10,['jpm16'],['abbv'],https://twitter.com/abbvie/status/687069091711074304,False,,1,https://pbs.twimg.com/media/CYj1ssTUoAAj8pr.jpg,,,,,,,[],,,,
660471787222917120,660471787222917120,2015-10-31 20:31:59 IST,2015-10-31,20:31:59,+0530,531892451,abbvie,AbbVie,,"‚ÄúWe have the potential to launch more than 20 new products or indications through 2020.‚Äù - R. Gonzalez, CEO $ABBV  https://t.co/vLhDO8AtFv",en,[],[],['https://pbs.twimg.com/media/CSp3lx7UEAAtOHi.jpg'],0,19,12,[],['abbv'],https://twitter.com/abbvie/status/660471787222917120,False,,1,https://pbs.twimg.com/media/CSp3lx7UEAAtOHi.jpg,,,,,,,[],,,,
660048294803070977,660048294803070977,2015-10-30 16:29:11 IST,2015-10-30,16:29:11,+0530,531892451,abbvie,AbbVie,,Our Q3 results are above analyst expectations. Read more:  https://t.co/Ma4MLvUaqS $ABBV  https://t.co/iVC0MprsPS,en,[],['http://ow.ly/U28if'],['https://pbs.twimg.com/media/CSj2bTpUAAA_5Yi.jpg'],0,23,20,[],['abbv'],https://twitter.com/abbvie/status/660048294803070977,False,,1,https://pbs.twimg.com/media/CSj2bTpUAAA_5Yi.jpg,,,,,,,[],,,,
658655889654726656,658655889654726656,2015-10-26 20:16:15 IST,2015-10-26,20:16:15,+0530,18294275,fiercepharma,FiercePharma,,AbbVie treads lightly with Express Scripts after FDA warning for Viekira Pak  https://t.co/amlvjShBjg $ABBV #pharma by @EmilyWFierce,en,"[{'screen_name': 'emilywfierce', 'name': 'emily wasserman', 'id': '2279548740'}]",['http://www.fiercepharma.com/story/abbvie-treads-lightly-express-scripts-after-fda-warning-viekira-pak/2015-10-26'],[],0,2,4,['pharma'],['abbv'],https://twitter.com/FiercePharma/status/658655889654726656,False,,0,,,,,,,,[],,,,
654643993465233408,654643993465233408,2015-10-15 18:34:25 IST,2015-10-15,18:34:25,+0530,2279548740,emilywfierce,Emily Wasserman,,Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C:  http://t.co/TQtCPInHHg $ABBV $GILD #pharma,en,[],['http://www.fiercepharma.com/story/advera-abbvies-viekira-pak-riskier-gileads-harvoni-hep-c/2015-10-15'],[],0,4,3,['pharma'],"['abbv', 'gild']",https://twitter.com/EmilyWFierce/status/654643993465233408,False,,0,,,,,,,,[],,,,
651822573861232641,651822573861232641,2015-10-07 23:43:06 IST,2015-10-07,23:43:06,+0530,274233761,bradloncar,Brad Loncar,,Mark S. is on CNBC‚Ä¶.recommending $GILD $BIIB and $ABBV. He thinks AbbVie will be back to $70 sooner rather than later.,en,[],[],[],5,4,6,[],"['gild', 'biib', 'abbv']",https://twitter.com/bradloncar/status/651822573861232641,False,,0,,,,,,,,[],,,,
644835950363832320,644835950363832320,2015-09-18 17:00:45 IST,2015-09-18,17:00:45,+0530,15752608,bosbizdon,Don Seiffert,,"BREAKING: AbbVie $ABBV leases space for new research facility in Cambridge, first presence in Boston area  http://t.co/l5nHOR9eye",en,[],['http://bizj.us/1jasvs'],[],0,7,7,[],['abbv'],https://twitter.com/BosBizDon/status/644835950363832320,False,,0,,,,,,,,[],,,,
644256496130256897,644256496130256897,2015-09-17 02:38:13 IST,2015-09-17,02:38:13,+0530,15563814,loftus,Peter Loftus,,AbbVie hires JP Morgan banker Henry Gosebruch as chief strategy officer $ABBV  http://t.co/Hma4U9VlVy via @WSJ,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['http://on.wsj.com/1ihX6DQ'],[],1,17,10,[],['abbv'],https://twitter.com/Loftus/status/644256496130256897,False,,0,,,,,,,,[],,,,
624995436005326848,624995436005326848,2015-07-25 23:01:38 IST,2015-07-25,23:01:38,+0530,531892451,abbvie,AbbVie,,"We invest in science, technology &amp; brainpower because R&amp;D intensity fuels our growth. $ABBV  http://t.co/uiw6LWkqNy",en,[],[],['https://pbs.twimg.com/tweet_video_thumb/CKxuCZLWoAAV219.png'],0,9,12,[],['abbv'],https://twitter.com/abbvie/status/624995436005326848,False,,1,https://pbs.twimg.com/tweet_video_thumb/CKxuCZLWoAAV219.png,,,,,,,[],,,,
624559942343761920,624559942343761920,2015-07-24 18:11:08 IST,2015-07-24,18:11:08,+0530,42589787,newsquawk,Newsquawk,,US PRE-MARKET MOVERS:  Stancorp Financial $SFG +49.3% Amazon $AMZN +21.4% Starbuck $SBUX +4.4% Biogen $BIIB -11.7%  AbbVie $ABBV -3.4%,en,[],[],[],0,8,4,[],"['sfg', 'amzn', 'sbux', 'biib', 'abbv']",https://twitter.com/Newsquawk/status/624559942343761920,False,,0,,,,,,,,[],,,,
606076281680035840,606076281680035840,2015-06-03 18:03:40 IST,2015-06-03,18:03:40,+0530,545618159,wrigleytom,Tom Wrigley,,$HALO $ABBV  Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie   http://t.co/P1kFK4ZyuP  http://t.co/NiWERemJbW,en,[],['http://finance.yahoo.com/news/halozyme-enters-global-collaboration-licensing-123000973.html?soc_src=mediacontentstory&soc_trk=tw'],['https://pbs.twimg.com/media/CGk3KqJVIAATdXV.png'],0,8,5,[],"['halo', 'abbv']",https://twitter.com/WrigleyTom/status/606076281680035840,False,,1,https://pbs.twimg.com/media/CGk3KqJVIAATdXV.png,,,,,,,[],,,,
573625439777853440,573625439777853440,2015-03-06 04:55:36 IST,2015-03-06,04:55:36,+0530,13171622,pharmalot,pharmalot,,A $42 Billion Drug? Why AbbVie may have overpaid for Pharmacyclics  http://t.co/qSdcMN8BVU #pharma $ABBV $PCYC #cancer #lymphoma #leukemia,en,[],['http://blogs.wsj.com/pharmalot/2015/03/05/the-42-billion-drug-why-abbvie-may-have-overpaid-for-pharmacyclics/'],[],1,15,6,"['pharma', 'cancer', 'lymphoma', 'leukemia']","['abbv', 'pcyc']",https://twitter.com/pharmalot/status/573625439777853440,False,,0,,,,,,,,[],,,,
573336105342386176,573336105342386176,2015-03-05 09:45:54 IST,2015-03-05,09:45:54,+0530,15563814,loftus,Peter Loftus,,AbbVie to buy Pharmacyclics in $21 billion deal  http://t.co/R7XMcDe8Xl via @WSJ @jonathanrockoff $ABBV $PCYC,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}, {'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}]",['http://on.wsj.com/1zMkhra'],[],1,15,8,[],"['abbv', 'pcyc']",https://twitter.com/Loftus/status/573336105342386176,False,,0,,,,,,,,[],,,,
573331779802832896,573331779802832896,2015-03-05 09:28:42 IST,2015-03-05,09:28:42,+0530,26574283,cnbcnow,CNBC Now,,"BREAKING: Abbvie says it will acquire Pharmacyclics for $261.25/share in cash and equity, or approximately $21 billion. $ABBV $PCYC",en,[],[],[],4,44,12,[],"['abbv', 'pcyc']",https://twitter.com/CNBCnow/status/573331779802832896,False,,0,,,,,,,,[],,,,
573330832972251136,573330832972251136,2015-03-05 09:24:57 IST,2015-03-05,09:24:57,+0530,296924721,bloombergdeals,Bloomberg Deals,,AbbVie to buy Pharmacyclics for  $261.25-shr in cash &amp; stock:  http://t.co/TD9sYTg1W4 $abbv $pcyc,en,[],['http://ow.ly/JWYfm'],[],0,12,7,[],"['abbv', 'pcyc']",https://twitter.com/BloombergDeals/status/573330832972251136,False,,0,,,,,,,,[],,,,
569985592852914176,569985592852914176,2015-02-24 03:52:09 IST,2015-02-24,03:52:09,+0530,475524030,wallstjesus,JE$US,,$ABBV AbbVie given $80 PT by Deutsche Bank --  BUY rating.,en,[],[],[],0,7,5,[],['abbv'],https://twitter.com/WallStJesus/status/569985592852914176,False,,0,,,,,,,,[],,,,
547168365778059264,547168365778059264,2014-12-23 04:44:38 IST,2014-12-23,04:44:38,+0530,13171622,pharmalot,pharmalot,,Special sale price: Docs divided over discount on AbbVie hepatitis C drug.. read why here.  http://t.co/WajSMhVDhJ #pharma $ESRX $GILD $ABBV,en,[],['http://blogs.wsj.com/pharmalot/2014/12/22/special-sale-price-docs-divided-over-discount-on-abbvie-hepatitis-c-drug/'],[],0,9,7,['pharma'],"['esrx', 'gild', 'abbv']",https://twitter.com/pharmalot/status/547168365778059264,False,,0,,,,,,,,[],,,,
547105687927799808,547105687927799808,2014-12-23 00:35:35 IST,2014-12-23,00:35:35,+0530,19546277,yahoofinance,Yahoo Finance,,"Amazon‚Äôs holiday hopes, Gilead vs. AbbVie &amp; Caesars gambles on affiliate  http://t.co/hyBJKhykzw $GILD $ABBV $ESRX $AMZN $CZR",en,[],['http://yhoo.it/1GPpDYN'],[],0,2,4,[],"['gild', 'abbv', 'esrx', 'amzn', 'czr']",https://twitter.com/YahooFinance/status/547105687927799808,False,,0,,,,,,,,[],,,,
547031766016348160,547031766016348160,2014-12-22 19:41:51 IST,2014-12-22,19:41:51,+0530,531892451,abbvie,AbbVie,,#AbbVie treatment receives #FDA approval to treat chronic genotype 1 #HCV:  http://t.co/1EnTFtRuda $ABBV,en,[],['http://bit.ly/1jTqn6z'],[],2,13,12,"['abbvie', 'fda', 'hcv']",['abbv'],https://twitter.com/abbvie/status/547031766016348160,False,,0,,,,,,,,[],,,,
546594067040452608,546594067040452608,2014-12-21 14:42:35 IST,2014-12-21,14:42:35,+0530,449681624,h3nphlo,H3NPHLO,,BMO: We Believe That In Many Cases Gilead‚Äôs #Harvoni Will Have an Advantage Over AbbVie‚Äôs #Viekira. $GILD $ABBV #HCV  http://t.co/EbIQOzYgkq,en,[],[],['https://pbs.twimg.com/media/B5XkW_-CYAEEFjy.png'],2,22,25,"['harvoni', 'viekira', 'hcv']","['gild', 'abbv']",https://twitter.com/H3NPHLO/status/546594067040452608,False,,1,https://pbs.twimg.com/media/B5XkW_-CYAEEFjy.png,,,,,,,[],,,,
546298464460869632,546298464460869632,2014-12-20 19:07:58 IST,2014-12-20,19:07:58,+0530,102754598,johncendpts,John Carroll,,"UPDATED: AbbVie wins blockbuster hep C approval, but shuns a deep discount on price $ABBV $GILD  http://t.co/gmGeOiqqaC",en,[],['http://www.fiercebiotech.com/story/abbvies-blockbuster-hep-c-approval-puts-it-toe-toe-gilead/2014-12-19'],[],0,9,8,[],"['abbv', 'gild']",https://twitter.com/JohnCendpts/status/546298464460869632,False,,0,,,,,,,,[],,,,
546207729816055808,546207729816055808,2014-12-20 13:07:25 IST,2014-12-20,13:07:25,+0530,1330741110,tomsilver39,Tom Silver,,"BMO"" $ABBV Viekira Label Worse Than We Expected, Price In Line; We‚Äôre Cautious on the Launch,net price AbbVie will book is roughly $73,000""",en,[],[],[],1,3,5,[],['abbv'],https://twitter.com/TomSilver39/status/546207729816055808,False,,0,,,,,,,,[],,,,
546076619731783680,546076619731783680,2014-12-20 04:26:26 IST,2014-12-20,04:26:26,+0530,531892451,abbvie,AbbVie,,BREAKING: $ABBV #hepatitisC drug receives #FDA approval  http://t.co/1EnTFtRuda,en,[],['http://bit.ly/1jTqn6z'],[],6,47,23,"['hepatitisc', 'fda']",['abbv'],https://twitter.com/abbvie/status/546076619731783680,False,,0,,,,,,,,[],,,,
535864725213437952,535864725213437952,2014-11-22 00:08:01 IST,2014-11-22,00:08:01,+0530,531892451,abbvie,AbbVie,,"$ABBV‚Äôs investigational, all-oral #HCV treatment granted positive opinions by #EMA CHMP in the EU:  http://t.co/1EnTFtRuda",en,[],['http://bit.ly/1jTqn6z'],[],0,14,9,"['hcv', 'ema']",[],https://twitter.com/abbvie/status/535864725213437952,False,,0,,,,,,,,[],,,,
522434621611712512,522434621611712512,2014-10-15 22:41:34 IST,2014-10-15,22:41:34,+0530,105926515,chen_liyan,Liyan Chen,,Abbvie is close to abandoning its tax inversion deal with Shire. What else to come?  http://t.co/b0cQuuVfd5 $ABBV $SHP  http://t.co/J8bJMrGrJJ,en,[],['http://onforb.es/1Bsk6EW'],['https://pbs.twimg.com/media/B0APhPzCYAAN5E5.jpg'],1,24,13,[],"['abbv', 'shp']",https://twitter.com/chen_liyan/status/522434621611712512,False,,1,https://pbs.twimg.com/media/B0APhPzCYAAN5E5.jpg,,,,,,,[],,,,
473830254428303360,473830254428303360,2014-06-03 19:45:10 IST,2014-06-03,19:45:10,+0530,531892451,abbvie,AbbVie,,"‚Ç¨85M investment creates greater manufacturing capacity for $ABBV following expansion of Sligo, Ireland facility  http://t.co/zNqd34oOAD",en,[],[],['https://pbs.twimg.com/media/BpNiGsaCMAAgJzG.jpg'],0,7,8,[],['abbv'],https://twitter.com/abbvie/status/473830254428303360,False,,1,https://pbs.twimg.com/media/BpNiGsaCMAAgJzG.jpg,,,,,,,[],,,,
